source: qrda/C0Q/trunk/kids/C0Q*1.0*3.DONTUSE@ 1501

Last change on this file since 1501 was 1497, checked in by Sam Habiel, 12 years ago

Childhood Immunizations (NQF0038)

File size: 85.8 KB
Line 
1KIDS Distribution saved on Jul 27, 2012@15:36:38
2SDFGHJKLXCVBNM,WERTYUI
3**KIDS**:C0Q*1.0*3^
4
5**INSTALL NAME**
6C0Q*1.0*3
7"BLD",7936,0)
8C0Q*1.0*3^QUALITY MEASURES^0^3120727^y
9"BLD",7936,1,0)
10^^5^5^3120713^
11"BLD",7936,1,1,0)
12Created by Sam Habiel on July 13th 2012 for distribution with WorldVistA
13"BLD",7936,1,2,0)
142.0.
15"BLD",7936,1,3,0)
16
17"BLD",7936,1,4,0)
18Contains updated C0Q QUALITY MEASURES file containing the appropriate
19"BLD",7936,1,5,0)
20rule sets to use after each measure.
21"BLD",7936,4,0)
22^9.64PA^1130580001.101^1
23"BLD",7936,4,1130580001.101,0)
241130580001.101
25"BLD",7936,4,1130580001.101,222)
26y^y^f^^y^^y^o^n
27"BLD",7936,4,"B",1130580001.101,1130580001.101)
28
29"BLD",7936,6.3)
308
31"BLD",7936,"ABPKG")
32n
33"BLD",7936,"KRN",0)
34^9.67PA^779.2^20
35"BLD",7936,"KRN",.4,0)
36.4
37"BLD",7936,"KRN",.401,0)
38.401
39"BLD",7936,"KRN",.402,0)
40.402
41"BLD",7936,"KRN",.403,0)
42.403
43"BLD",7936,"KRN",.5,0)
44.5
45"BLD",7936,"KRN",.84,0)
46.84
47"BLD",7936,"KRN",3.6,0)
483.6
49"BLD",7936,"KRN",3.8,0)
503.8
51"BLD",7936,"KRN",9.2,0)
529.2
53"BLD",7936,"KRN",9.8,0)
549.8
55"BLD",7936,"KRN",19,0)
5619
57"BLD",7936,"KRN",19.1,0)
5819.1
59"BLD",7936,"KRN",101,0)
60101
61"BLD",7936,"KRN",409.61,0)
62409.61
63"BLD",7936,"KRN",771,0)
64771
65"BLD",7936,"KRN",779.2,0)
66779.2
67"BLD",7936,"KRN",870,0)
68870
69"BLD",7936,"KRN",8989.51,0)
708989.51
71"BLD",7936,"KRN",8989.52,0)
728989.52
73"BLD",7936,"KRN",8994,0)
748994
75"BLD",7936,"KRN","B",.4,.4)
76
77"BLD",7936,"KRN","B",.401,.401)
78
79"BLD",7936,"KRN","B",.402,.402)
80
81"BLD",7936,"KRN","B",.403,.403)
82
83"BLD",7936,"KRN","B",.5,.5)
84
85"BLD",7936,"KRN","B",.84,.84)
86
87"BLD",7936,"KRN","B",3.6,3.6)
88
89"BLD",7936,"KRN","B",3.8,3.8)
90
91"BLD",7936,"KRN","B",9.2,9.2)
92
93"BLD",7936,"KRN","B",9.8,9.8)
94
95"BLD",7936,"KRN","B",19,19)
96
97"BLD",7936,"KRN","B",19.1,19.1)
98
99"BLD",7936,"KRN","B",101,101)
100
101"BLD",7936,"KRN","B",409.61,409.61)
102
103"BLD",7936,"KRN","B",771,771)
104
105"BLD",7936,"KRN","B",779.2,779.2)
106
107"BLD",7936,"KRN","B",870,870)
108
109"BLD",7936,"KRN","B",8989.51,8989.51)
110
111"BLD",7936,"KRN","B",8989.52,8989.52)
112
113"BLD",7936,"KRN","B",8994,8994)
114
115"BLD",7936,"QUES",0)
116^9.62^^
117"BLD",7936,"REQB",0)
118^9.611^2^2
119"BLD",7936,"REQB",1,0)
120C0Q*1.0*2^2
121"BLD",7936,"REQB",2,0)
122QUALITY MEASURES 1.0^2
123"BLD",7936,"REQB","B","C0Q*1.0*2",1)
124
125"BLD",7936,"REQB","B","QUALITY MEASURES 1.0",2)
126
127"DATA",1130580001.101,1,0)
128M1^^^2.16.840.1.113883.3.249.11.2
129"DATA",1130580001.101,1,1)
130CMS Measure #1: Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus
131"DATA",1130580001.101,1,4)
132PQRI-1
133"DATA",1130580001.101,1,5)
134Hemoglobin A1c Poor Control in Diabetes Mellitus
135"DATA",1130580001.101,1,6,0)
136^^2^2^3101013^
137"DATA",1130580001.101,1,6,1,0)
138Percentage of patients 18 through 75 years with diabetes melli
139"DATA",1130580001.101,1,6,2,0)
140tus who had most recent hemoglobin A1C greater than 9.0%
141"DATA",1130580001.101,1,7)
142^^^^
143"DATA",1130580001.101,2,0)
144M5^^^2.16.840.1.113883.3.249.11.5
145"DATA",1130580001.101,2,1)
146CMS Measure #5: Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
147"DATA",1130580001.101,2,4)
148PQRI-5
149"DATA",1130580001.101,2,5)
150Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
151"DATA",1130580001.101,2,6,0)
152^^2^2^3101013^
153"DATA",1130580001.101,2,6,1,0)
154Percentage of patients 18 years and older with a diagnosis of
155"DATA",1130580001.101,2,6,2,0)
156heart failure and LVSD who were prescribed an ACE inhbitor or ARB therapy
157"DATA",1130580001.101,2,7)
158^^^^
159"DATA",1130580001.101,3,0)
160M112^^^2.16.840.1.113883.3.249.11.9
161"DATA",1130580001.101,3,1)
162Measure #112: Preventive Care and Screening: Screening Mammography
163"DATA",1130580001.101,3,4)
164PQRI-112
165"DATA",1130580001.101,3,5)
166Screening Mammography
167"DATA",1130580001.101,3,6,0)
168^1130580001.111^2^2^3101014^^
169"DATA",1130580001.101,3,6,1,0)
170Percentage of womaen aged 40 through 69 years who had a mammog
171"DATA",1130580001.101,3,6,2,0)
172ram to screen for breast cancer within 24 months
173"DATA",1130580001.101,3,7)
174^^^^
175"DATA",1130580001.101,4,0)
176M124^^^2.16.840.1.113883.3.249.11.11
177"DATA",1130580001.101,4,1)
178Measure #124: Health Information Technology (HIT): Adoption/Use of Electronic Health Records
179"DATA",1130580001.101,4,4)
180PQRI-124
181"DATA",1130580001.101,4,5)
182Adoption/Use of Electronic Health Records (EHR)
183"DATA",1130580001.101,4,6,0)
184^^3^3^3101013^
185"DATA",1130580001.101,4,6,1,0)
186Documents whether provider has adopted and is using health inf
187"DATA",1130580001.101,4,6,2,0)
188ormation technology. To qualify, the provider must havea adopted and be
189"DATA",1130580001.101,4,6,3,0)
190using a certified/qualified electronic health record (EHR)
191"DATA",1130580001.101,4,7)
192^^^^
193"DATA",1130580001.101,5,0)
194M128^^^2.16.840.1.113883.3.249.11.54
195"DATA",1130580001.101,5,1)
196Measure #128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
197"DATA",1130580001.101,5,4)
198PQRI-128
199"DATA",1130580001.101,5,5)
200Body Mass Index (BMI) Screening and Follow-Up
201"DATA",1130580001.101,5,6,0)
202^1130580001.111^5^5^3101014^^
203"DATA",1130580001.101,5,6,1,0)
204Percentage of patients aged 18 yesrs and older with a calculate BMI in
205"DATA",1130580001.101,5,6,2,0)
206the past 6 months or during the current visit documented in the medical
207"DATA",1130580001.101,5,6,3,0)
208record and if the most recent BMI is ourtide parameters, a follow-up plan
209"DATA",1130580001.101,5,6,4,0)
210is documented. Ages 65 and older BMI equal to or greater than 30 or less
211"DATA",1130580001.101,5,6,5,0)
212than 22 and ages 18-64, BMI greater than or equal to 25 or less than 18.5
213"DATA",1130580001.101,5,7)
214^^^^
215"DATA",1130580001.101,6,0)
216M47^^^2.16.840.1.113883.3.249.11.52
217"DATA",1130580001.101,6,1)
218Measure #47: Advance Care Plan
219"DATA",1130580001.101,6,4)
220PQRI-47
221"DATA",1130580001.101,6,5)
222Advance Care Plan
223"DATA",1130580001.101,6,6,0)
224^1130580001.111^5^5^3101014^^^
225"DATA",1130580001.101,6,6,1,0)
226Percentage of patients age 65 and older who have an advanced care plan or
227"DATA",1130580001.101,6,6,2,0)
228surrogate decision maker documented in the medical record or documented
229"DATA",1130580001.101,6,6,3,0)
230in the medical record that an advance care plan was discussed but the
231"DATA",1130580001.101,6,6,4,0)
232patient did not wish or was not able to name a surrogate decision maker
233"DATA",1130580001.101,6,6,5,0)
234or provide an advance care plan.
235"DATA",1130580001.101,6,7)
236^^^^
237"DATA",1130580001.101,7,0)
238M48^^^2.16.840.1.113883.3.249.11.53
239"DATA",1130580001.101,7,1)
240Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
241"DATA",1130580001.101,7,4)
242PQRI-48
243"DATA",1130580001.101,7,5)
244Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
245"DATA",1130580001.101,7,6,0)
246^^3^3^3101013^
247"DATA",1130580001.101,7,6,1,0)
248Percentage of patients equal to or older than 65 years of age at the
249"DATA",1130580001.101,7,6,2,0)
250beginning of the measurement perion who were assesed for the presence or
251"DATA",1130580001.101,7,6,3,0)
252absence of urinary incontinence within 12 months
253"DATA",1130580001.101,7,7)
254^^^^
255"DATA",1130580001.101,8,0)
256M2^^^2.16.840.1.113883.3.249.11.3
257"DATA",1130580001.101,8,1)
258Measure #2: Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
259"DATA",1130580001.101,8,4)
260PQRI-2
261"DATA",1130580001.101,8,5)
262Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
263"DATA",1130580001.101,8,6,0)
264^^2^2^3101013^
265"DATA",1130580001.101,8,6,1,0)
266Percentage of patients 18 through 75 years with diabetes melli
267"DATA",1130580001.101,8,6,2,0)
268tus who had most recent LDL-C level in control (less than 100 mg./dL)
269"DATA",1130580001.101,8,7)
270^^^^
271"DATA",1130580001.101,9,0)
272M3^^^2.16.840.1.113883.3.249.11.4
273"DATA",1130580001.101,9,1)
274CMS Measure #3: Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus - QRDA Cat I template
275"DATA",1130580001.101,9,4)
276PQRI-3
277"DATA",1130580001.101,9,5)
278High Blood Pressure Control in Diabetes Mellitus
279"DATA",1130580001.101,9,6,0)
280^^2^2^3101013^
281"DATA",1130580001.101,9,6,1,0)
282Percentage of patients 18 through 75 years with diabetes melli
283"DATA",1130580001.101,9,6,2,0)
284tus who had most recent blood pressure in control (less than 140/80 mmHg)
285"DATA",1130580001.101,9,7)
286^^^^
287"DATA",1130580001.101,10,0)
288M7^^^2.16.840.1.113883.3.249.11.6
289"DATA",1130580001.101,10,1)
290CMS Measure #7: Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)
291"DATA",1130580001.101,10,4)
292PQRI-7
293"DATA",1130580001.101,10,5)
294Percentage of patients 18 aged 18 years and older wit a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy
295"DATA",1130580001.101,10,6,0)
296^^3^3^3101013^
297"DATA",1130580001.101,10,6,1,0)
298Percentage of patients aged 18 years and older with a diagnosis of
299"DATA",1130580001.101,10,6,2,0)
300coronary artery disease and a prior MI who where prescribed beta-blocker
301"DATA",1130580001.101,10,6,3,0)
302therapy
303"DATA",1130580001.101,10,7)
304^^^^
305"DATA",1130580001.101,11,0)
306M110^^^2.16.840.1.113883.3.249.11.7
307"DATA",1130580001.101,11,1)
308Measure #110: Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years
309"DATA",1130580001.101,11,4)
310PQRI-110
311"DATA",1130580001.101,11,5)
312Influenza Immunization for Patients >= 50 Years
313"DATA",1130580001.101,11,6,0)
314^1130580001.111^2^2^3101014^^
315"DATA",1130580001.101,11,6,1,0)
316Percentage of patients aged 50 years and older who received an
317"DATA",1130580001.101,11,6,2,0)
318 influenza immunization during the flu season (September through February)
319"DATA",1130580001.101,11,7)
320^^^^
321"DATA",1130580001.101,12,0)
322M111^^^2.16.840.1.113883.3.249.11.8
323"DATA",1130580001.101,12,1)
324Measure #111: Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older
325"DATA",1130580001.101,12,4)
326PQRI-111
327"DATA",1130580001.101,12,5)
328Pneumonia Vaccination for Patients 65 Years and Older
329"DATA",1130580001.101,12,6,0)
330^^2^2^3101013^
331"DATA",1130580001.101,12,6,1,0)
332Percentage of patients afed 65 years and older who have ever r
333"DATA",1130580001.101,12,6,2,0)
334eceived a pneumoccal vaccine
335"DATA",1130580001.101,12,7)
336^^^^
337"DATA",1130580001.101,13,0)
338M113^^^2.16.840.1.113883.3.249.11.10
339"DATA",1130580001.101,13,1)
340Measure #113: Preventive Care and Screening: Colorectal Cancer Screening
341"DATA",1130580001.101,13,4)
342PQRI-113
343"DATA",1130580001.101,13,5)
344Colorectal Cancer Screening
345"DATA",1130580001.101,13,6,0)
346^^2^2^3101013^
347"DATA",1130580001.101,13,6,1,0)
348Percentage of patients aged 50 through 80 who received the app
349"DATA",1130580001.101,13,6,2,0)
350ropriate colorectal cancer screening
351"DATA",1130580001.101,13,7)
352^^^^
353"DATA",1130580001.101,14,0)
354M39^^^2.16.840.1.113883.3.249.11.51
355"DATA",1130580001.101,14,1)
356Measure #39: Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
357"DATA",1130580001.101,14,4)
358PQRI-39
359"DATA",1130580001.101,14,5)
360Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
361"DATA",1130580001.101,14,6,0)
362^^3^3^3101013^
363"DATA",1130580001.101,14,6,1,0)
364Percentage of patients who had a DXA measurement ordered or pe
365"DATA",1130580001.101,14,6,2,0)
366rformed at least once since age 60 or pharmacologic therapy prescribed
367"DATA",1130580001.101,14,6,3,0)
368within 12 months before the end of the measurement period
369"DATA",1130580001.101,14,7)
370^^^^
371"DATA",1130580001.101,16,0)
372M173^^^2.16.840.1.113883.3.249.11.55
373"DATA",1130580001.101,16,1)
374Measure #173: Preventive Care and Screening: Unhealthy Alcohol Use - Screening
375"DATA",1130580001.101,16,4)
376PQRI-173
377"DATA",1130580001.101,16,5)
378Preventive Care and Screening: Unhealthy Alcohol Use - Screening
379"DATA",1130580001.101,16,6,0)
380^^2^2^3101013^
381"DATA",1130580001.101,16,6,1,0)
382Percentage of patients aged 18 years and older who were screen
383"DATA",1130580001.101,16,6,2,0)
384ed for unhealthy alcohol use using a systematic method within 24 months
385"DATA",1130580001.101,16,7)
386^^^^
387"DATA",1130580001.101,17,0)
388M0013^^^2.16.840.1.113883.3.249.11.56
389"DATA",1130580001.101,17,1)
390Measure #0013: Hypertension (HTN): Blood Pressure Measurement - QRDA Cat I template
391"DATA",1130580001.101,17,4)
392PQRI-13
393"DATA",1130580001.101,17,5)
394Hypertension (HTN): Blood Pressure Measurement
395"DATA",1130580001.101,17,6,0)
396^1130580001.111^3^3^3110412^^
397"DATA",1130580001.101,17,6,1,0)
398Percentage of patients aged 18 years and older with a diagnosi
399"DATA",1130580001.101,17,6,2,0)
400s of hypertension in the beginning of the measurement period with a blood
401"DATA",1130580001.101,17,6,3,0)
402pressure recorded
403"DATA",1130580001.101,17,7)
404^^^^
405"DATA",1130580001.101,18,0)
406M0022^^^2.16.840.1.113883.3.249.11.57
407"DATA",1130580001.101,18,1)
408Measure #0022: Drugs to be avoided in the Elderly
409"DATA",1130580001.101,18,4)
410PQRI-22
411"DATA",1130580001.101,18,5)
412Drugs to be avoided in the elderly
413"DATA",1130580001.101,18,6,0)
414^^2^2^3101013^
415"DATA",1130580001.101,18,6,1,0)
416Percentage of patients aged 65 years and older who received at least one
417"DATA",1130580001.101,18,6,2,0)
418drug to be avoided in the elderly in the measurement period
419"DATA",1130580001.101,18,7)
420^^^^
421"DATA",1130580001.101,19,0)
422M0028^^^2.16.840.1.113883.3.249.11.59
423"DATA",1130580001.101,19,1)
424Measure #0028: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
425"DATA",1130580001.101,19,4)
426PQRI-28
427"DATA",1130580001.101,19,5)
428Preventive care and Screening: Tobacco Use: Screening and Cessation Intervention
429"DATA",1130580001.101,19,6,0)
430^^4^4^3101013^
431"DATA",1130580001.101,19,6,1,0)
432Percentage of patients aged 18 years of older who were screene
433"DATA",1130580001.101,19,6,2,0)
434d about tobacco use at least once during the two year measurement period
435"DATA",1130580001.101,19,6,3,0)
436AND who received smoking cessation counseling if identified as a tobacco
437"DATA",1130580001.101,19,6,4,0)
438user
439"DATA",1130580001.101,19,7)
440^^^^
441"DATA",1130580001.101,20,0)
442M0038^^^2.16.840.1.113883.3.249.11.60
443"DATA",1130580001.101,20,1)
444Measure #0038: Childhood Immunization Status
445"DATA",1130580001.101,20,4)
446PQRI-38
447"DATA",1130580001.101,20,5)
448Childhood immumnization status
449"DATA",1130580001.101,20,6,0)
450^^4^4^3101013^
451"DATA",1130580001.101,20,6,1,0)
452Percentage of children who turn two years of age during the me
453"DATA",1130580001.101,20,6,2,0)
454asurement period who have had 4 DTaP/DT, 3 IPV, 1 MMR and 3 H influenza
455"DATA",1130580001.101,20,6,3,0)
456type B, 3 hepatitis B, 1 chicken pox vaccine (VZV) and 4 pneumoccal
457"DATA",1130580001.101,20,6,4,0)
458conjugate vaccines by their second birthday
459"DATA",1130580001.101,20,7)
460^^^^
461"DATA",1130580001.101,21,0)
462M0024^^
463"DATA",1130580001.101,21,7)
464^^^^
465"DATA",1130580001.101,22,0)
466TEST M0028A^^^2.16.840.1.113883.3.249.11.59
467"DATA",1130580001.101,22,1)
468Measure #0028: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
469"DATA",1130580001.101,22,4)
470PQRI-28
471"DATA",1130580001.101,22,5)
472Preventive care and Screening: Tobacco Use: Screening and Cessation Intervention
473"DATA",1130580001.101,22,6,0)
474^1130580001.111^4^4^3110427^^^^
475"DATA",1130580001.101,22,6,1,0)
476Percentage of patients aged 18 years of older who were screene
477"DATA",1130580001.101,22,6,2,0)
478d about tobacco use at least once during the two year measurement period
479"DATA",1130580001.101,22,6,3,0)
480AND who received smoking cessation counseling if identified as a tobacco
481"DATA",1130580001.101,22,6,4,0)
482user
483"DATA",1130580001.101,22,7)
484^^^^
485"DATA",1130580001.101,23,0)
486MU HOS NQF 0495^^
487"DATA",1130580001.101,23,1)
488ED THROUGHPUT ARRIVAL TO DEPARTURE
489"DATA",1130580001.101,23,5)
490ED THROUGHPUT ARRIVAL TO DEPARTURE
491"DATA",1130580001.101,23,6,0)
492^1130580001.111^3^3^3110430^^^^
493"DATA",1130580001.101,23,6,1,0)
494Median time from emergency department arrival to time of departure from
495"DATA",1130580001.101,23,6,2,0)
496the emergency room for patients admitted to the facility from the
497"DATA",1130580001.101,23,6,3,0)
498emergency department
499"DATA",1130580001.101,23,7)
500NQF0495^^^^^^88^165
501"DATA",1130580001.101,24,0)
502MU HOS NQF 0497^^
503"DATA",1130580001.101,24,1)
504ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
505"DATA",1130580001.101,24,5)
506ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
507"DATA",1130580001.101,24,6,0)
508^^3^3^3110430^
509"DATA",1130580001.101,24,6,1,0)
510Median time from admit decision time to time of departure from the
511"DATA",1130580001.101,24,6,2,0)
512emergency department of emergency department patients admitted to
513"DATA",1130580001.101,24,6,3,0)
514inpatient status
515"DATA",1130580001.101,24,7)
516NQF0497^^^^^^90^168
517"DATA",1130580001.101,25,0)
518MU HOS NQF 0435^^
519"DATA",1130580001.101,25,1)
520Ischemic stroke.Discharge on anti-thrombotics
521"DATA",1130580001.101,25,5)
522 Ischemic stroke.Discharge on anti-thrombotic
523"DATA",1130580001.101,25,6,0)
524^^2^2^3110430^
525"DATA",1130580001.101,25,6,1,0)
526Ischemic stroke patients prescribed antithrombotic therapy at hospital
527"DATA",1130580001.101,25,6,2,0)
528discharge
529"DATA",1130580001.101,25,7)
530NQF0435^^^^^^114^115
531"DATA",1130580001.101,26,0)
532MU HOS NQF 0436^^
533"DATA",1130580001.101,26,1)
534 Ischemic stroke.Anticoagulation for A-fib/flutter
535"DATA",1130580001.101,26,5)
536Ischemic stroke.Anticoagulation for A-fib/flutter
537"DATA",1130580001.101,26,6,0)
538^1130580001.111^2^2^3110430^^^
539"DATA",1130580001.101,26,6,1,0)
540 Ischemic stroke patients with atrial fibrillation/flutter who are
541"DATA",1130580001.101,26,6,2,0)
542prescribed anticoagulation therapy at hospital discharge
543"DATA",1130580001.101,26,7)
544NQF0436^^^^^^116^117
545"DATA",1130580001.101,27,0)
546MU HOS NQF 0437^^
547"DATA",1130580001.101,27,1)
548 Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
549"DATA",1130580001.101,27,5)
550Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
551"DATA",1130580001.101,27,6,0)
552^^3^3^3110430^
553"DATA",1130580001.101,27,6,1,0)
554Acute ischemic stroke patients who arrive at this hospital within 2
555"DATA",1130580001.101,27,6,2,0)
556hours of time last known well and for whom IV t-PA was initiated at this
557"DATA",1130580001.101,27,6,3,0)
558hospital within 3 hours of time last known well.
559"DATA",1130580001.101,27,7)
560NQF0437^^^^^^119^118
561"DATA",1130580001.101,28,0)
562MU HOS NQF 0438^^
563"DATA",1130580001.101,28,1)
564Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
565"DATA",1130580001.101,28,5)
566Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
567"DATA",1130580001.101,28,6,0)
568^^2^2^3110430^
569"DATA",1130580001.101,28,6,1,0)
570Ischemic stroke patients administered antithrombotic therapy by the
571"DATA",1130580001.101,28,6,2,0)
572end of hospital day 2.
573"DATA",1130580001.101,28,7)
574NQF0438^^^^^^120^121
575"DATA",1130580001.101,29,0)
576MU HOS NQF 0439^^
577"DATA",1130580001.101,29,1)
578Ischemic stroke.Discharge on statins
579"DATA",1130580001.101,29,5)
580Ischemic stroke.Discharge on statins
581"DATA",1130580001.101,29,6,0)
582^^3^3^3110430^
583"DATA",1130580001.101,29,6,1,0)
584Ischemic stroke patients with LDL > 100 mg/dL, or LDL not measured, or,
585"DATA",1130580001.101,29,6,2,0)
586who were on a lipid-lowering medication prior to hospital arrival are
587"DATA",1130580001.101,29,6,3,0)
588prescribed statin medication at hospital discharge
589"DATA",1130580001.101,29,7)
590NQF0439^^^^^^122^123
591"DATA",1130580001.101,30,0)
592MU HOS NQF 0440^^
593"DATA",1130580001.101,30,1)
594Ischemic or hemorrhagic stroke.Stroke education
595"DATA",1130580001.101,30,5)
596Ischemic or hemorrhagic stroke.Stroke education
597"DATA",1130580001.101,30,6,0)
598^^5^5^3110430^
599"DATA",1130580001.101,30,6,1,0)
600Ischemic or hemorrhagic stroke patients or their caregivers who were
601"DATA",1130580001.101,30,6,2,0)
602given educational materials during the hospital stay addressing all of the
603"DATA",1130580001.101,30,6,3,0)
604following: activation of emergency medical system, need for follow-up
605"DATA",1130580001.101,30,6,4,0)
606after discharge, medications prescribed at discharge, risk factors for
607"DATA",1130580001.101,30,6,5,0)
608stroke, and warning signs and symptoms of stroke.
609"DATA",1130580001.101,30,7)
610NQF0440^^^^^^124^125
611"DATA",1130580001.101,31,0)
612MU HOS NQF 0441^^
613"DATA",1130580001.101,31,1)
614Ischemic or hemorrhagic stroke.Rehabilitation assessment
615"DATA",1130580001.101,31,5)
616Ischemic or hemorrhagic stroke.Rehabilitation assessment
617"DATA",1130580001.101,31,6,0)
618^^2^2^3110430^
619"DATA",1130580001.101,31,6,1,0)
620Ischemic or hemorrhagic stroke patients who were assessed for
621"DATA",1130580001.101,31,6,2,0)
622rehabilitation services.
623"DATA",1130580001.101,31,7)
624NQF0441^^^^^^126^127
625"DATA",1130580001.101,32,0)
626MU HOS NQF 0371^^
627"DATA",1130580001.101,32,1)
628VTE prophylaxis within 24 hours of arrival
629"DATA",1130580001.101,32,5)
630VTE prophylaxis within 24 hours of arrival
631"DATA",1130580001.101,32,6,0)
632^^4^4^3110430^
633"DATA",1130580001.101,32,6,1,0)
634This measure assesses the number of patients who received VTE prophylaxis
635"DATA",1130580001.101,32,6,2,0)
636or have documentation why no VTE prophylaxis was given the day of or the
637"DATA",1130580001.101,32,6,3,0)
638day after hospital admission or surgery end date for surgeries that start
639"DATA",1130580001.101,32,6,4,0)
640the day of or the day after hospital admission.
641"DATA",1130580001.101,32,7)
642NQF0371^^^^^^69^67
643"DATA",1130580001.101,33,0)
644MU HOS NQF 0372^^
645"DATA",1130580001.101,33,1)
646ICU VTE prophylaxis
647"DATA",1130580001.101,33,5)
648ICU VTE prophylaxis
649"DATA",1130580001.101,33,6,0)
650^^5^5^3110430^
651"DATA",1130580001.101,33,6,1,0)
652This measure assesses the number of patients who received VTE prophylaxis
653"DATA",1130580001.101,33,6,2,0)
654or have documentation why no VTE prophylaxis was given the day of or the
655"DATA",1130580001.101,33,6,3,0)
656day after the initial admission (or transfer) to the Intensive Care Unit
657"DATA",1130580001.101,33,6,4,0)
658(ICU) or surgery end date for surgeries that start the day of or the day
659"DATA",1130580001.101,33,6,5,0)
660after ICU admission (or transfer).
661"DATA",1130580001.101,33,7)
662NQF0372^^^^^^128^71
663"DATA",1130580001.101,34,0)
664MU HOS NQF 0373^^
665"DATA",1130580001.101,34,1)
666Anticoagulation overlap therapy
667"DATA",1130580001.101,34,5)
668Anticoagulation overlap therapy
669"DATA",1130580001.101,34,6,0)
670^^8^8^3110430^
671"DATA",1130580001.101,34,6,1,0)
672This measure assesses the number of patients diagnosed with confirmed VTE
673"DATA",1130580001.101,34,6,2,0)
674who received an overlap of parenteral (intravenous [IV] or subcutaneous
675"DATA",1130580001.101,34,6,3,0)
676[subcu]) anticoagulation and warfarin therapy. For patients who received
677"DATA",1130580001.101,34,6,4,0)
678less than five days of overlap therapy, they must be discharged on both
679"DATA",1130580001.101,34,6,5,0)
680medications. Overlap therapy must be administered for at least five days
681"DATA",1130580001.101,34,6,6,0)
682with an international normalized ratio (INR) . 2 prior to discontinuation
683"DATA",1130580001.101,34,6,7,0)
684of the parenteral anticoagulation therapy or the patient must be
685"DATA",1130580001.101,34,6,8,0)
686discharged on both medications.
687"DATA",1130580001.101,34,7)
688NQF0373^^^^^^129^144
689"DATA",1130580001.101,35,0)
690MU HOS NQF 0374^^
691"DATA",1130580001.101,35,1)
692Platelet monitoring on unfractionated heparin
693"DATA",1130580001.101,35,5)
694Platelet monitoring on unfractionated heparin
695"DATA",1130580001.101,35,6,0)
696^^10^10^3110430^
697"DATA",1130580001.101,35,6,1,0)
698This measure assesses the number of patients diagnosed with confirmed VTE
699"DATA",1130580001.101,35,6,2,0)
700who received intravenous (IV) UFH therapy dosages AND had their platelet
701"DATA",1130580001.101,35,6,3,0)
702counts monitored using defined parameters such as a nomogram or
703"DATA",1130580001.101,35,6,4,0)
704protocol This measure assesses the number of patients diagnosed with
705"DATA",1130580001.101,35,6,5,0)
706confirmed VTE who received intravenous (IV) UFH therapy dosages AND had
707"DATA",1130580001.101,35,6,6,0)
708their platelet counts monitored using defined parameters such as a
709"DATA",1130580001.101,35,6,7,0)
710nomogram or protocol This measure assesses the number of patients
711"DATA",1130580001.101,35,6,8,0)
712diagnosed with confirmed VTE who received intravenous (IV) UFH therapy
713"DATA",1130580001.101,35,6,9,0)
714dosages AND had their platelet counts monitored using defined parameters
715"DATA",1130580001.101,35,6,10,0)
716such as a nomogram or protocol
717"DATA",1130580001.101,35,7)
718NQF0374^^^^^^145^146
719"DATA",1130580001.101,36,0)
720MU HOS NQF 0375^^
721"DATA",1130580001.101,36,1)
722VTE discharge instructions
723"DATA",1130580001.101,36,5)
724VTE discharge instructions
725"DATA",1130580001.101,36,6,0)
726^^11^11^3110430^
727"DATA",1130580001.101,36,6,1,0)
728This measure assesses the number of patients diagnosed with confirmed VTE
729"DATA",1130580001.101,36,6,2,0)
730that are discharged to home, to home with home health, home hospice or
731"DATA",1130580001.101,36,6,3,0)
732discharged/transferred to court/law enforcement on warfarin with written
733"DATA",1130580001.101,36,6,4,0)
734discharge instructions that address all four criteria: compliance issues,
735"DATA",1130580001.101,36,6,5,0)
736dietary advice, follow-up This measure assesses the number of patients
737"DATA",1130580001.101,36,6,6,0)
738diagnosed with confirmed VTE that are discharged to home, to home with
739"DATA",1130580001.101,36,6,7,0)
740home health, home hospice or discharged/transferred to court/law
741"DATA",1130580001.101,36,6,8,0)
742enforcement on warfarin with written discharge instructions that address
743"DATA",1130580001.101,36,6,9,0)
744all four criteria: compliance issues, dietary advice, follow-up
745"DATA",1130580001.101,36,6,10,0)
746monitoring, and information about the potential for adverse drug
747"DATA",1130580001.101,36,6,11,0)
748reactions/interactions.
749"DATA",1130580001.101,36,7)
750NQF0375^^^^^^147^156
751"DATA",1130580001.101,37,0)
752MU HOS NQF 0376^^
753"DATA",1130580001.101,37,1)
754Incidence of potentially preventable VTE
755"DATA",1130580001.101,37,5)
756Incidence of potentially preventable VTE
757"DATA",1130580001.101,37,6,0)
758^^4^4^3110430^
759"DATA",1130580001.101,37,6,1,0)
760This measure assesses the number of patients diagnosed with confirmed VTE
761"DATA",1130580001.101,37,6,2,0)
762during hospitalization (not present on arrival) who did not receive VTE
763"DATA",1130580001.101,37,6,3,0)
764prophylaxis between hospital admission and the day before the VTE
765"DATA",1130580001.101,37,6,4,0)
766diagnostic testing order date.
767"DATA",1130580001.101,37,7)
768NQF0376^^^^^^158^162
769"DATA",1130580001.101,38,0)
77012^^
771"DATA",1130580001.101,38,7)
772^^^^
773"DATA",1130580001.101,39,0)
774MU EP NQF 0421^^
775"DATA",1130580001.101,39,1)
776NQF0421 Adult Weight Screening and Follow-Up
777"DATA",1130580001.101,39,5)
778NQF0421 Adult Weight Screening and Follow-Up
779"DATA",1130580001.101,39,6,0)
780^1130580001.111^6^6^3110628^^^^
781"DATA",1130580001.101,39,6,1,0)
782Percentage of patients aged 18
783"DATA",1130580001.101,39,6,2,0)
784years and older with a calculated BMI in the past
785"DATA",1130580001.101,39,6,3,0)
786six months or during the current visit documented in
787"DATA",1130580001.101,39,6,4,0)
788the medical record AND if the most recent BMI is
789"DATA",1130580001.101,39,6,5,0)
790outside parameters, a follow-up plan is
791"DATA",1130580001.101,39,6,6,0)
792documented.
793"DATA",1130580001.101,39,7)
794NQF0421^^^^^^321^320^10
795"DATA",1130580001.101,40,0)
796MU EP NQF 0013^^
797"DATA",1130580001.101,40,1)
798NQF0013 Hypertension: Blood Pressure Measurement
799"DATA",1130580001.101,40,5)
800NQF0013 Hypertension: Blood Pressure Measurement
801"DATA",1130580001.101,40,6,0)
802^1130580001.111^4^4^3120712^^^
803"DATA",1130580001.101,40,6,1,0)
804Percentage of patient visits for patients
805"DATA",1130580001.101,40,6,2,0)
806aged 18 years and older with a diagnosis of hypertension
807"DATA",1130580001.101,40,6,3,0)
808who have been seen for at least 2 office visits, with blood
809"DATA",1130580001.101,40,6,4,0)
810pressure (BP) recorded
811"DATA",1130580001.101,40,7)
812NQF0013^^^^^^142^167
813"DATA",1130580001.101,41,0)
814MU EP NQF 0028A^^
815"DATA",1130580001.101,41,1)
816NQF0028A Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention
817"DATA",1130580001.101,41,5)
818NQF0028A Tobacco Use Assessment
819"DATA",1130580001.101,41,6,0)
820^1130580001.111^7^7^3110625^^^
821"DATA",1130580001.101,41,6,1,0)
822 Percentage of patients aged 18 years and
823"DATA",1130580001.101,41,6,2,0)
824older who have been seen for at least 2 office visits who
825"DATA",1130580001.101,41,6,3,0)
826were queried about tobacco use one or more times within
827"DATA",1130580001.101,41,6,4,0)
82824 months b. Percentage of patients aged 18 years and
829"DATA",1130580001.101,41,6,5,0)
830older identified as tobacco users within the past 24
831"DATA",1130580001.101,41,6,6,0)
832months and have been seen for at least 2 office visits,
833"DATA",1130580001.101,41,6,7,0)
834who received cessation intervention.
835"DATA",1130580001.101,41,7)
836NQF0028A^^^^^^157^160
837"DATA",1130580001.101,42,0)
838MU EP NQF 0041^^
839"DATA",1130580001.101,42,1)
840Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years Old
841"DATA",1130580001.101,42,5)
842NQF0041 Influenza Immunization 50 years and older
843"DATA",1130580001.101,42,6,0)
844^^4^4^3110430^
845"DATA",1130580001.101,42,6,1,0)
846Percentage of patients aged 50 years
847"DATA",1130580001.101,42,6,2,0)
848and older who received an influenza immunization
849"DATA",1130580001.101,42,6,3,0)
850during the flu season (September through
851"DATA",1130580001.101,42,6,4,0)
852February).
853"DATA",1130580001.101,42,7)
854NQF0041^^^^^^242^243
855"DATA",1130580001.101,43,0)
856MU EP NQF 0024^^
857"DATA",1130580001.101,43,1)
858NQF0024 Weight Assessment and Counseling for Children and Adolescents
859"DATA",1130580001.101,43,5)
860NQF0024 Weight Assessment and Counseling for Children and Adolescents
861"DATA",1130580001.101,43,6,0)
862^1130580001.111^6^6^3120713^^
863"DATA",1130580001.101,43,6,1,0)
864Percentage of patients 2 -17 years of age
865"DATA",1130580001.101,43,6,2,0)
866who had an outpatient visit with a Primary Care Physician
867"DATA",1130580001.101,43,6,3,0)
868(PCP) or OB/GYN and who had evidence of BMI
869"DATA",1130580001.101,43,6,4,0)
870percentile documentation, counseling for nutrition and
871"DATA",1130580001.101,43,6,5,0)
872counseling for physical activity during the measurement
873"DATA",1130580001.101,43,6,6,0)
874year.
875"DATA",1130580001.101,43,7)
876NQF0024^^^^^^151^149
877"DATA",1130580001.101,44,0)
878MU EP NQF 0038^^
879"DATA",1130580001.101,44,1)
880Childhood Immunization Status
881"DATA",1130580001.101,44,5)
882Childhood Immunization Status
883"DATA",1130580001.101,44,6,0)
884^^14^14^3110430^
885"DATA",1130580001.101,44,6,1,0)
886Percentage of children 2 years of age who
887"DATA",1130580001.101,44,6,2,0)
888had four diphtheria, tetanus and acellular pertussis
889"DATA",1130580001.101,44,6,3,0)
890(DTaP); three polio(IPV), one measles, ,mumps and
891"DATA",1130580001.101,44,6,4,0)
892rubella (MMR); two H influenza type B (HiB); three
893"DATA",1130580001.101,44,6,5,0)
894Percentage of children 2 years of age who
895"DATA",1130580001.101,44,6,6,0)
896had four diphtheria, tetanus and acellular pertussis
897"DATA",1130580001.101,44,6,7,0)
898(DTaP); three polio(IPV), one measles, ,mumps and
899"DATA",1130580001.101,44,6,8,0)
900rubella (MMR); two H influenza type B (HiB); three
901"DATA",1130580001.101,44,6,9,0)
902hepatitis B (Hep B); one chicken pox (VZV); four
903"DATA",1130580001.101,44,6,10,0)
904pneumococcal conjugate (PCV); two hepatitis A (Hep A);
905"DATA",1130580001.101,44,6,11,0)
906two or three rotavirus (RV); and two influenza (flu)
907"DATA",1130580001.101,44,6,12,0)
908vaccines by their second birthday. The measure
909"DATA",1130580001.101,44,6,13,0)
910calculates a rate for each vaccine and nine separate
911"DATA",1130580001.101,44,6,14,0)
912combination rates.
913"DATA",1130580001.101,44,7)
914NQF0038^^^^
915"DATA",1130580001.101,45,0)
916MU EP NQF 0059^^
917"DATA",1130580001.101,45,1)
918Diabetes: Hemoglobin A1c Poor Contro
919"DATA",1130580001.101,45,5)
920Diabetes: NQF0059 Hemoglobin A1c Poor Control
921"DATA",1130580001.101,45,6,0)
922^1130580001.111^2^2^3120716^^
923"DATA",1130580001.101,45,6,1,0)
924Percentage of patients 18 - 75 years of age with diabetes (type 1
925"DATA",1130580001.101,45,6,2,0)
926or type 2) who had hemoglobin A1c > 9.0%.
927"DATA",1130580001.101,45,7)
928NQF0059^^^^^^260^258
929"DATA",1130580001.101,46,0)
930MU EP NQF 0064^^
931"DATA",1130580001.101,46,1)
932Diabetes: Low Density Lipoprotein (LDL) Management and Control
933"DATA",1130580001.101,46,5)
934NQF0064 Diabetes: Low Density Lipoprotein (LDL) Management and Control
935"DATA",1130580001.101,46,6,0)
936^^3^3^3110430^
937"DATA",1130580001.101,46,6,1,0)
938Percentage of patients 18-75 years of age with diabetes (type 1
939"DATA",1130580001.101,46,6,2,0)
940or type 2) who had LDL-C < 100 mg/dL).Percentage of patients 18-75 years
941"DATA",1130580001.101,46,6,3,0)
942of age with diabetes (type 1 or type 2) who had LDL-C < 100 mg/dL).
943"DATA",1130580001.101,46,7)
944NQF0064^^^^^^248^258
945"DATA",1130580001.101,47,0)
946MU EP NQF 0061^^
947"DATA",1130580001.101,47,1)
948Blood Pressure Management
949"DATA",1130580001.101,47,5)
950NQF0061 Diabetes: Blood Pressure Management
951"DATA",1130580001.101,47,6,0)
952^^2^2^3110430^
953"DATA",1130580001.101,47,6,1,0)
954Percentage of patients 18 - 75 years of age with
955"DATA",1130580001.101,47,6,2,0)
956diabetes (type 1 or type 2) who had blood pressure <140/90 mmHg.
957"DATA",1130580001.101,47,7)
958NQF0061^^^^^^262^258
959"DATA",1130580001.101,48,0)
960MU EP NQF 0081^^
961"DATA",1130580001.101,48,1)
962Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
963"DATA",1130580001.101,48,5)
964Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
965"DATA",1130580001.101,48,6,0)
966^^3^3^3110430^
967"DATA",1130580001.101,48,6,1,0)
968Percentage of patients aged 18 years and older with a
969"DATA",1130580001.101,48,6,2,0)
970diagnosis of heart failure and LVSD (LVEF < 40%) who were
971"DATA",1130580001.101,48,6,3,0)
972prescribed ACE inhibitor or ARB therapy
973"DATA",1130580001.101,48,7)
974NQF0081^^^^
975"DATA",1130580001.101,49,0)
976MU EP NQF 0070^^
977"DATA",1130580001.101,49,1)
978Pneumonia Vaccination Status for Older Adults
979"DATA",1130580001.101,49,5)
980Pneumonia Vaccination Status for Older Adults
981"DATA",1130580001.101,49,6,0)
982^^2^2^3110430^
983"DATA",1130580001.101,49,6,1,0)
984Percentage of patients 65 years of age and older who have ever
985"DATA",1130580001.101,49,6,2,0)
986received a pneumococcal vaccine.
987"DATA",1130580001.101,49,7)
988NQF0070^^^^
989"DATA",1130580001.101,50,0)
990MU EP NQF 0031^^
991"DATA",1130580001.101,50,1)
992Breast Cancer Screening
993"DATA",1130580001.101,50,5)
994Breast Cancer Screening
995"DATA",1130580001.101,50,6,0)
996^^2^2^3110430^
997"DATA",1130580001.101,50,6,1,0)
998Percentage of women 40-69 years of age who had a
999"DATA",1130580001.101,50,6,2,0)
1000mammogram to screen for breast cancer
1001"DATA",1130580001.101,50,7)
1002NQF0031^^^^
1003"DATA",1130580001.101,51,0)
1004MU EP NQF 0034^^
1005"DATA",1130580001.101,51,1)
1006Colorectal Cancer Screening
1007"DATA",1130580001.101,51,5)
1008Colorectal Cancer Screening
1009"DATA",1130580001.101,51,6,0)
1010^^2^2^3110430^
1011"DATA",1130580001.101,51,6,1,0)
1012Percentage of adults 50-75 years of age who had appropriate screening for
1013"DATA",1130580001.101,51,6,2,0)
1014colorectal cancer.
1015"DATA",1130580001.101,51,7)
1016NQF0034^^^^
1017"DATA",1130580001.101,52,0)
1018MU EP NQF 0067^^
1019"DATA",1130580001.101,52,1)
1020Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
1021"DATA",1130580001.101,52,5)
1022Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
1023"DATA",1130580001.101,52,6,0)
1024^^2^2^3110430^
1025"DATA",1130580001.101,52,6,1,0)
1026Percentage of patients aged 18 years and older with a
1027"DATA",1130580001.101,52,6,2,0)
1028diagnosis of CAD who were prescribed oral antiplatelet therapy.
1029"DATA",1130580001.101,52,7)
1030NQF0067^^^^
1031"DATA",1130580001.101,53,0)
1032MU EP NQF 0083^^
1033"DATA",1130580001.101,53,1)
1034Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
1035"DATA",1130580001.101,53,5)
1036Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
1037"DATA",1130580001.101,53,6,0)
1038^^3^3^3110430^
1039"DATA",1130580001.101,53,6,1,0)
1040Percentage of patients aged 18 years and older with a
1041"DATA",1130580001.101,53,6,2,0)
1042diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were
1043"DATA",1130580001.101,53,6,3,0)
1044prescribed beta-blocker therapy
1045"DATA",1130580001.101,53,7)
1046NQF0083^^^^
1047"DATA",1130580001.101,54,0)
1048MU EP NQF 0105^^
1049"DATA",1130580001.101,54,1)
1050Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment
1051"DATA",1130580001.101,54,5)
1052Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment
1053"DATA",1130580001.101,54,6,0)
1054^^4^4^3110430^
1055"DATA",1130580001.101,54,6,1,0)
1056The percentage of patients 18 years of age and older
1057"DATA",1130580001.101,54,6,2,0)
1058who were diagnosed with a new episode of major depression, treated
1059"DATA",1130580001.101,54,6,3,0)
1060with antidepressant medication, and who remained on an
1061"DATA",1130580001.101,54,6,4,0)
1062antidepressant medication treatment.
1063"DATA",1130580001.101,54,7)
1064NQF0105^^^^
1065"DATA",1130580001.101,55,0)
1066MU EP NQF 0086^^
1067"DATA",1130580001.101,55,1)
1068Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
1069"DATA",1130580001.101,55,5)
1070Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
1071"DATA",1130580001.101,55,6,0)
1072^^4^4^3110430^
1073"DATA",1130580001.101,55,6,1,0)
1074Percentage of patients aged 18 years and older with a
1075"DATA",1130580001.101,55,6,2,0)
1076diagnosis of POAG who have been seen for at least two office visits
1077"DATA",1130580001.101,55,6,3,0)
1078who have an optic nerve head evaluation during one or more office
1079"DATA",1130580001.101,55,6,4,0)
1080visits within 12 months.
1081"DATA",1130580001.101,55,7)
1082NQF0086^^^^
1083"DATA",1130580001.101,56,0)
1084MU EP NQF 0088^^
1085"DATA",1130580001.101,56,1)
1086Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
1087"DATA",1130580001.101,56,5)
1088Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
1089"DATA",1130580001.101,56,6,0)
1090^^5^5^3110430^
1091"DATA",1130580001.101,56,6,1,0)
1092Percentage of patients aged 18 years and older with a
1093"DATA",1130580001.101,56,6,2,0)
1094diagnosis of diabetic retinopathy who had a dilated macular or fundus
1095"DATA",1130580001.101,56,6,3,0)
1096exam performed which included documentation of the level of severity
1097"DATA",1130580001.101,56,6,4,0)
1098of retinopathy and the presence or absence of macular edema during
1099"DATA",1130580001.101,56,6,5,0)
1100one or more office visits within 12 months.
1101"DATA",1130580001.101,56,7)
1102NQF0088^^^^
1103"DATA",1130580001.101,57,0)
1104MU EP NQF 0089^^
1105"DATA",1130580001.101,57,1)
1106Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
1107"DATA",1130580001.101,57,5)
1108Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
1109"DATA",1130580001.101,57,6,0)
1110^^6^6^3110430^
1111"DATA",1130580001.101,57,6,1,0)
1112Percentage of patients aged 18 years and older with a
1113"DATA",1130580001.101,57,6,2,0)
1114diagnosis of diabetic retinopathy who had a dilated macular or fundus
1115"DATA",1130580001.101,57,6,3,0)
1116exam performed with documented communication to the physician who
1117"DATA",1130580001.101,57,6,4,0)
1118manages the ongoing care of the patient with diabetes mellitus
1119"DATA",1130580001.101,57,6,5,0)
1120regarding the findings of the macular or fundus exam at least once
1121"DATA",1130580001.101,57,6,6,0)
1122within 12 months.
1123"DATA",1130580001.101,57,7)
1124NQF0089^^^^
1125"DATA",1130580001.101,58,0)
1126MU EP NQF 0047^^
1127"DATA",1130580001.101,58,1)
1128Asthma Pharmacologic Therapy
1129"DATA",1130580001.101,58,5)
1130Asthma Pharmacologic Therapy
1131"DATA",1130580001.101,58,6,0)
1132^1130580001.111^4^4^3110430^^
1133"DATA",1130580001.101,58,6,1,0)
1134Percentage of patients aged 5 through 40 years with a
1135"DATA",1130580001.101,58,6,2,0)
1136diagnosis of mild, moderate, or severe persistent asthma who were
1137"DATA",1130580001.101,58,6,3,0)
1138prescribed either the preferred long-term control medication (inhaled
1139"DATA",1130580001.101,58,6,4,0)
1140corticosteroid) or an acceptable alternative treatment
1141"DATA",1130580001.101,58,7)
1142NQF0047^^^^
1143"DATA",1130580001.101,59,0)
1144MU EP NQF 0001^^
1145"DATA",1130580001.101,59,1)
1146Asthma Assessment
1147"DATA",1130580001.101,59,5)
1148Asthma Assessment
1149"DATA",1130580001.101,59,6,0)
1150^^5^5^3110430^
1151"DATA",1130580001.101,59,6,1,0)
1152Percentage of patients aged 5 through 40 years with a
1153"DATA",1130580001.101,59,6,2,0)
1154diagnosis of asthma and who have been seen for at least 2 office
1155"DATA",1130580001.101,59,6,3,0)
1156visits, who were evaluated during at least one office visit within 12
1157"DATA",1130580001.101,59,6,4,0)
1158months for the frequency (numeric) of daytime and nocturnal asthma
1159"DATA",1130580001.101,59,6,5,0)
1160symptoms.
1161"DATA",1130580001.101,59,7)
1162NQF0001^^^^
1163"DATA",1130580001.101,60,0)
1164MU EP NQF 0002^^
1165"DATA",1130580001.101,60,1)
1166Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breat Cancer
1167"DATA",1130580001.101,60,5)
1168Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
1169"DATA",1130580001.101,60,6,0)
1170^^4^4^3110430^
1171"DATA",1130580001.101,60,6,1,0)
1172Percentage of female patients aged 18 years and older
1173"DATA",1130580001.101,60,6,2,0)
1174with Stage IC through IIIC, ER or PR positive breast cancer who were
1175"DATA",1130580001.101,60,6,3,0)
1176prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month
1177"DATA",1130580001.101,60,6,4,0)
1178reporting period.
1179"DATA",1130580001.101,60,7)
1180NQF0002^^^^
1181"DATA",1130580001.101,61,0)
1182MU EP NQF 0385^^
1183"DATA",1130580001.101,61,1)
1184Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
1185"DATA",1130580001.101,61,5)
1186Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
1187"DATA",1130580001.101,61,6,0)
1188^^4^4^3110430^
1189"DATA",1130580001.101,61,6,1,0)
1190Percentage of patients aged 18 years and older with
1191"DATA",1130580001.101,61,6,2,0)
1192Stage IIIA through IIIC colon cancer who are referred for adjuvant
1193"DATA",1130580001.101,61,6,3,0)
1194chemotherapy, prescribed adjuvant chemotherapy, or have previously
1195"DATA",1130580001.101,61,6,4,0)
1196received adjuvant chemotherapy within the 12-month reporting period
1197"DATA",1130580001.101,61,7)
1198NQF0385^^^^
1199"DATA",1130580001.101,62,0)
1200MU EP NQF 0389^^
1201"DATA",1130580001.101,62,1)
1202Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
1203"DATA",1130580001.101,62,5)
1204Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
1205"DATA",1130580001.101,62,6,0)
1206^^5^5^3110430^
1207"DATA",1130580001.101,62,6,1,0)
1208Percentage of patients, regardless of age, with a diagnosis of
1209"DATA",1130580001.101,62,6,2,0)
1210prostate cancer at low risk of recurrence receiving interstitial prostate
1211"DATA",1130580001.101,62,6,3,0)
1212brachytherapy, OR external beam radiotherapy to the prostate, OR radical
1213"DATA",1130580001.101,62,6,4,0)
1214prostatectomy, OR cryotherapy who did not have a bone scan performed at
1215"DATA",1130580001.101,62,6,5,0)
1216any time since diagnosis of prostate cancer.
1217"DATA",1130580001.101,62,7)
1218NQF0389^^^^
1219"DATA",1130580001.101,63,0)
1220MU EP NQF 0027^^
1221"DATA",1130580001.101,63,1)
1222Smoking Smokers and Tobacco Users to Quit,b. Discussing Smoking and Tobacco use Cessation Medications, c. Discussing Smoking and Tobacco use Cessation Strategies and Tobacco Use Cessation, Medical assistance: a. Advising
1223"DATA",1130580001.101,63,5)
1224Smoking and Tobacco Use Cessation
1225"DATA",1130580001.101,63,6,0)
1226^^5^5^3110430^
1227"DATA",1130580001.101,63,6,1,0)
1228Percentage of patients 18 years of age and older who were
1229"DATA",1130580001.101,63,6,2,0)
1230current smokers or tobacco users, who were seen by a practitioner during
1231"DATA",1130580001.101,63,6,3,0)
1232the measurement year and who received advice to quit smoking or tobacco
1233"DATA",1130580001.101,63,6,4,0)
1234use or whose practitioner recommended or discussed smoking or tobacco use
1235"DATA",1130580001.101,63,6,5,0)
1236cessation medications, methods or strategies
1237"DATA",1130580001.101,63,7)
1238NQF0027^^^^
1239"DATA",1130580001.101,64,0)
1240MU EP NQF 0055^^
1241"DATA",1130580001.101,64,1)
1242Diabetes: Eye Exam
1243"DATA",1130580001.101,64,5)
1244Diabetes: Eye Exam
1245"DATA",1130580001.101,64,6,0)
1246^^3^3^3110430^
1247"DATA",1130580001.101,64,6,1,0)
1248Percentage of patients 18 -75 years of age with diabetes (type 1
1249"DATA",1130580001.101,64,6,2,0)
1250or type 2) who had a retinal or dilated eye exam or a negative retinal
1251"DATA",1130580001.101,64,6,3,0)
1252exam (no evidence of retinopathy) by an eye care professional
1253"DATA",1130580001.101,64,7)
1254NQF0055^^^^
1255"DATA",1130580001.101,65,0)
1256MU EP NQF 0062^^
1257"DATA",1130580001.101,65,1)
1258Diabetes: Urine Screening
1259"DATA",1130580001.101,65,5)
1260Diabetes: Urine Screening
1261"DATA",1130580001.101,65,6,0)
1262^^3^3^3110430^
1263"DATA",1130580001.101,65,6,1,0)
1264Percentage of patients 18 - 75 years of age with diabetes (type 1
1265"DATA",1130580001.101,65,6,2,0)
1266or type 2) who had a nephropathy screening test or evidence of
1267"DATA",1130580001.101,65,6,3,0)
1268nephropathy.
1269"DATA",1130580001.101,65,7)
1270NQF0062^^^^
1271"DATA",1130580001.101,66,0)
1272MU EP NQF 0056^^
1273"DATA",1130580001.101,66,1)
1274Diabetes: Foot Exam
1275"DATA",1130580001.101,66,5)
1276Diabetes: Foot Exam
1277"DATA",1130580001.101,66,6,0)
1278^^3^3^3110430^
1279"DATA",1130580001.101,66,6,1,0)
1280The percentage of patients aged 18 - 75 years with diabetes
1281"DATA",1130580001.101,66,6,2,0)
1282(type 1 or type 2) who had a foot exam (visual inspection, sensory exam
1283"DATA",1130580001.101,66,6,3,0)
1284with monofilament, or pulse exam).
1285"DATA",1130580001.101,66,7)
1286NQF0056^^^^
1287"DATA",1130580001.101,67,0)
1288MU EP NQF 0074^^
1289"DATA",1130580001.101,67,1)
1290Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
1291"DATA",1130580001.101,67,5)
1292Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
1293"DATA",1130580001.101,67,6,0)
1294^^3^3^3110430^
1295"DATA",1130580001.101,67,6,1,0)
1296Percentage of patients aged 18 years and older with a
1297"DATA",1130580001.101,67,6,2,0)
1298diagnosis of CAD who were prescribed a lipid-lowering therapy (based
1299"DATA",1130580001.101,67,6,3,0)
1300on current ACC/AHA guidelines).
1301"DATA",1130580001.101,67,7)
1302NQF0074^^^^
1303"DATA",1130580001.101,68,0)
1304MU EP NQF 0084^^
1305"DATA",1130580001.101,68,1)
1306Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
1307"DATA",1130580001.101,68,5)
1308Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
1309"DATA",1130580001.101,68,6,0)
1310^^3^3^3110430^
1311"DATA",1130580001.101,68,6,1,0)
1312Percentage of all patients aged 18 years and older with a
1313"DATA",1130580001.101,68,6,2,0)
1314diagnosis of heart failure and paroxysmal or chronic atrial fibrillation
1315"DATA",1130580001.101,68,6,3,0)
1316who were prescribed warfarin therapy.
1317"DATA",1130580001.101,68,7)
1318NQF0084^^^^
1319"DATA",1130580001.101,69,0)
1320MU EP NQF 0073^^
1321"DATA",1130580001.101,69,1)
1322Ischemic Vascular Disease (IVD): Blood Pressure Management
1323"DATA",1130580001.101,69,5)
1324Ischemic Vascular Disease (IVD): Blood Pressure Management
1325"DATA",1130580001.101,69,6,0)
1326^^11^11^3110430^
1327"DATA",1130580001.101,69,6,1,0)
1328Percentage of patients 18 years of age and older who
1329"DATA",1130580001.101,69,6,2,0)
1330were discharged alive for acute myocardial infarction (AMI), coronary
1331"DATA",1130580001.101,69,6,3,0)
1332artery bypass graft (CABG) or percutaneous transluminal coronary
1333"DATA",1130580001.101,69,6,4,0)
1334Percentage of patients 18 years of age and older who
1335"DATA",1130580001.101,69,6,5,0)
1336were discharged alive for acute myocardial infarction (AMI), coronary
1337"DATA",1130580001.101,69,6,6,0)
1338artery bypass graft (CABG) or percutaneous transluminal coronary
1339"DATA",1130580001.101,69,6,7,0)
1340angioplasty (PTCA) from January 1- November 1 of the year prior to
1341"DATA",1130580001.101,69,6,8,0)
1342the measurement year, or who had a diagnosis of ischemic vascular
1343"DATA",1130580001.101,69,6,9,0)
1344disease (IVD) during the measurement year and the year prior to the
1345"DATA",1130580001.101,69,6,10,0)
1346measurement year and whose recent blood pressure is in control
1347"DATA",1130580001.101,69,6,11,0)
1348(<140/90 mmHg).
1349"DATA",1130580001.101,69,7)
1350NQF0073^^^^
1351"DATA",1130580001.101,70,0)
1352MU EP NQF 0068^^
1353"DATA",1130580001.101,70,1)
1354Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
1355"DATA",1130580001.101,70,5)
1356 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
1357"DATA",1130580001.101,70,6,0)
1358^^8^8^3110430^
1359"DATA",1130580001.101,70,6,1,0)
1360 Percentage of patients 18 years of age and older who were
1361"DATA",1130580001.101,70,6,2,0)
1362discharged alive for acute myocardial infarction (AMI), coronary artery
1363"DATA",1130580001.101,70,6,3,0)
1364bypass graft (CABG) or percutaneous transluminal coronary
1365"DATA",1130580001.101,70,6,4,0)
1366angioplasty (PTCA) from January 1-November 1 of the year prior to the
1367"DATA",1130580001.101,70,6,5,0)
1368measurement year, or who had a diagnosis of ischemic vascular
1369"DATA",1130580001.101,70,6,6,0)
1370disease (IVD) during the measurement year and the year prior to the
1371"DATA",1130580001.101,70,6,7,0)
1372measurement year and who had documentation of use of aspirin or
1373"DATA",1130580001.101,70,6,8,0)
1374another antithrombotic during the measurement year
1375"DATA",1130580001.101,70,7)
1376NQF0068^^^^
1377"DATA",1130580001.101,71,0)
1378MU EP NQF 0004^^
1379"DATA",1130580001.101,71,1)
1380 Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a)Initiation,(b)Engagement
1381"DATA",1130580001.101,71,5)
1382Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a) Initiation,(b) Engagement
1383"DATA",1130580001.101,71,6,0)
1384^^6^6^3110430^
1385"DATA",1130580001.101,71,6,1,0)
1386The percentage of adolescent and adult patients with a new
1387"DATA",1130580001.101,71,6,2,0)
1388episode of alcohol and other drug (AOD) dependence who initiate treatment
1389"DATA",1130580001.101,71,6,3,0)
1390through an inpatient AOD admission, outpatient visit, intensive
1391"DATA",1130580001.101,71,6,4,0)
1392outpatient encounter or partial hospitalization within 14 days of the
1393"DATA",1130580001.101,71,6,5,0)
1394diagnosis and who initiated treatment and who had two or more additional
1395"DATA",1130580001.101,71,6,6,0)
1396services with an AOD diagnosis within 30 days of the initiation visit.
1397"DATA",1130580001.101,71,7)
1398NQF0004^^^^
1399"DATA",1130580001.101,72,0)
1400MU EP NQF 0012^^
1401"DATA",1130580001.101,72,1)
1402Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
1403"DATA",1130580001.101,72,5)
1404Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
1405"DATA",1130580001.101,72,6,0)
1406^^3^3^3110430^
1407"DATA",1130580001.101,72,6,1,0)
1408Percentage of patients, regardless of age, who gave birth during
1409"DATA",1130580001.101,72,6,2,0)
1410a 12-month period who were screened for HIV infection during the first or
1411"DATA",1130580001.101,72,6,3,0)
1412second prenatal care visit.
1413"DATA",1130580001.101,72,7)
1414NQF0012^^^^
1415"DATA",1130580001.101,73,0)
1416MU EP NQF 0014^^
1417"DATA",1130580001.101,73,1)
1418Prenatal Care: Anti-D Immune Globulin
1419"DATA",1130580001.101,73,5)
1420Prenatal Care: Anti-D Immune Globulin
1421"DATA",1130580001.101,73,6,0)
1422^^3^3^3110430^
1423"DATA",1130580001.101,73,6,1,0)
1424Percentage of D (Rh) negative, unsensitized patients, regardless
1425"DATA",1130580001.101,73,6,2,0)
1426of age, who gave birth during a 12-month period who received anti-D
1427"DATA",1130580001.101,73,6,3,0)
1428immune globulin at 26-30 weeks gestation.
1429"DATA",1130580001.101,73,7)
1430NQD0014^^^^
1431"DATA",1130580001.101,74,0)
1432MU EP NQF 0018^^
1433"DATA",1130580001.101,74,1)
1434Controlling High Blood Pressure
1435"DATA",1130580001.101,74,5)
1436Controlling High Blood Pressure
1437"DATA",1130580001.101,74,6,0)
1438^^3^3^3110430^
1439"DATA",1130580001.101,74,6,1,0)
1440The percentage of patients 18-85 years of age who had a
1441"DATA",1130580001.101,74,6,2,0)
1442diagnosis of hypertension and whose BP was adequately controlled during
1443"DATA",1130580001.101,74,6,3,0)
1444the measurement year
1445"DATA",1130580001.101,74,7)
1446NQF0018^^^^
1447"DATA",1130580001.101,75,0)
1448MU EP NQF 0032^^
1449"DATA",1130580001.101,75,1)
1450Cervical Cancer Screening
1451"DATA",1130580001.101,75,5)
1452Cervical Cancer Screening
1453"DATA",1130580001.101,75,6,0)
1454^^2^2^3110430^
1455"DATA",1130580001.101,75,6,1,0)
1456Percentage of women 21-64 years of age, who received one or
1457"DATA",1130580001.101,75,6,2,0)
1458more Pap tests to screen for cervical cancer
1459"DATA",1130580001.101,75,7)
1460NQF0032^^^^
1461"DATA",1130580001.101,76,0)
1462MU EP NQF 0033^^
1463"DATA",1130580001.101,76,1)
1464Chlamydia Screening for Women
1465"DATA",1130580001.101,76,5)
1466Chlamydia Screening for Women
1467"DATA",1130580001.101,76,6,0)
1468^^3^3^3110430^
1469"DATA",1130580001.101,76,6,1,0)
1470Percentage of women 15- 24 years of age who were identified as sexually
1471"DATA",1130580001.101,76,6,2,0)
1472active and who had at least one test for chlamydia during the measurement
1473"DATA",1130580001.101,76,6,3,0)
1474year.
1475"DATA",1130580001.101,76,7)
1476NQF0033^^^^
1477"DATA",1130580001.101,77,0)
1478MU EP NQF 0036^^
1479"DATA",1130580001.101,77,1)
1480Use of Appropriate Medications for Asthma
1481"DATA",1130580001.101,77,5)
1482Use of Appropriate Medications for Asthma
1483"DATA",1130580001.101,77,6,0)
1484^^4^4^3110430^
1485"DATA",1130580001.101,77,6,1,0)
1486Percentage of patients 5 - 50 years of age who were identified as having
1487"DATA",1130580001.101,77,6,2,0)
1488persistent asthma and were appropriately prescribed medication during the
1489"DATA",1130580001.101,77,6,3,0)
1490measurement year. Report three age stratifications (5-11 years, 12-50
1491"DATA",1130580001.101,77,6,4,0)
1492years, and total).
1493"DATA",1130580001.101,77,7)
1494NQF0036^^^^
1495"DATA",1130580001.101,78,0)
1496MU EP NQF 0052^^
1497"DATA",1130580001.101,78,1)
1498Low Back Pain: Use of Imaging Studies
1499"DATA",1130580001.101,78,5)
1500Low Back Pain: Use of Imaging Studies
1501"DATA",1130580001.101,78,6,0)
1502^1130580001.111^3^3^3110430^^
1503"DATA",1130580001.101,78,6,1,0)
1504Percentage of patients with a primary diagnosis of low back pain
1505"DATA",1130580001.101,78,6,2,0)
1506who did not have an imaging study (plain x-ray, MRI, CT scan) within 28
1507"DATA",1130580001.101,78,6,3,0)
1508days of diagnosis.
1509"DATA",1130580001.101,78,7)
1510NQF0052^^^^
1511"DATA",1130580001.101,79,0)
1512MU EP NQF 0075^^
1513"DATA",1130580001.101,79,1)
1514Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
1515"DATA",1130580001.101,79,5)
1516Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
1517"DATA",1130580001.101,79,6,0)
1518^^7^7^3110430^
1519"DATA",1130580001.101,79,6,1,0)
1520Percentage of patients 18 years of age and older who were discharged alive
1521"DATA",1130580001.101,79,6,2,0)
1522for acute myocardial infarction (AMI), coronary artery bypass graft (CABG)
1523"DATA",1130580001.101,79,6,3,0)
1524or percutaneous transluminal angioplasty (PTCA) from January 1-November1
1525"DATA",1130580001.101,79,6,4,0)
1526of the year prior to the measurement year, or who had a diagnosis of
1527"DATA",1130580001.101,79,6,5,0)
1528ischemic vascular disease (IVD) during the measurement year and the year
1529"DATA",1130580001.101,79,6,6,0)
1530prior to the measurement year and who had a complete lipid profile
1531"DATA",1130580001.101,79,6,7,0)
1532performed during the measurement year and whose LDL-C<100 mg/dL
1533"DATA",1130580001.101,79,7)
1534NQF0075^^^^
1535"DATA",1130580001.101,80,0)
1536MU EP NQF 0575^^
1537"DATA",1130580001.101,80,1)
1538Diabetes: Hemoglobin A1c Control (<8.0%)
1539"DATA",1130580001.101,80,5)
1540Diabetes: Hemoglobin A1c Control (<8.0%)
1541"DATA",1130580001.101,80,6,0)
1542^^2^2^3110430^
1543"DATA",1130580001.101,80,6,1,0)
1544The percentage of patients 18-75 years of age with diabetes
1545"DATA",1130580001.101,80,6,2,0)
1546(type 1 or type 2) who had hemoglobin A1c <8.0%
1547"DATA",1130580001.101,80,7)
1548NQF0575^^^^
1549"DATA",1130580001.101,81,0)
1550MU EP NQF 0028B^^
1551"DATA",1130580001.101,81,1)
1552NQF0028B Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention
1553"DATA",1130580001.101,81,5)
1554NQF0028B Tobacco Use Assessment and Cessation Intervention
1555"DATA",1130580001.101,81,6,0)
1556^1130580001.111^7^7^3110625^^^^
1557"DATA",1130580001.101,81,6,1,0)
1558 Percentage of patients aged 18 years and
1559"DATA",1130580001.101,81,6,2,0)
1560older who have been seen for at least 2 office visits who
1561"DATA",1130580001.101,81,6,3,0)
1562were queried about tobacco use one or more times within
1563"DATA",1130580001.101,81,6,4,0)
156424 months b. Percentage of patients aged 18 years and
1565"DATA",1130580001.101,81,6,5,0)
1566older identified as tobacco users within the past 24
1567"DATA",1130580001.101,81,6,6,0)
1568months and have been seen for at least 2 office visits,
1569"DATA",1130580001.101,81,6,7,0)
1570who received cessation intervention.
1571"DATA",1130580001.101,81,7)
1572NQF0028B^^^^^^154^160
1573"DATA",1130580001.101,82,0)
1574MU EP 0028B^^
1575"DATA",1130580001.101,82,7)
1576^^^^
1577"DATA",1130580001.101,83,0)
1578NQF0038 NUM1 DPT^^
1579"DATA",1130580001.101,83,5)
1580NQF0038 NUM1 DPT
1581"DATA",1130580001.101,83,7)
1582NQF0038 NUM1 DPT^^^^^^329^192^11
1583"DATA",1130580001.101,84,0)
1584NQF0038 NUM2 IPV^^
1585"DATA",1130580001.101,84,5)
1586NQF0038 NUM2 IPV
1587"DATA",1130580001.101,84,7)
1588NQF0038 NUM2 IPV^^^^^^224^192^11
1589"DATA",1130580001.101,85,0)
1590NQF0038 NUM3 MMR^^
1591"DATA",1130580001.101,85,5)
1592NQF0038 NUM3 MMR
1593"DATA",1130580001.101,85,7)
1594NQF0038 NUM3 MMR^^^^^^183^192^11
1595"DATA",1130580001.101,86,0)
1596NQF0038 NUM4 HiB^^
1597"DATA",1130580001.101,86,5)
1598NQF0038 NUM4 HiB
1599"DATA",1130580001.101,86,7)
1600NQF0038 NUM4 HiB^^^^^^189^192^11
1601"DATA",1130580001.101,87,0)
1602NQF0038 NUM5 HEP B^^
1603"DATA",1130580001.101,87,5)
1604NQF0038 NUM5 HEP B
1605"DATA",1130580001.101,87,7)
1606NQF0038 NUM5 HEP B^^^^^^194^192^11
1607"DATA",1130580001.101,88,0)
1608NQF0038 NUM6 VZV^^
1609"DATA",1130580001.101,88,5)
1610NQF0038 NUM6 VZV
1611"DATA",1130580001.101,88,7)
1612NQF0038 NUM6 VZV^^^^^^198^192^11
1613"DATA",1130580001.101,89,0)
1614NQF0038 NUM7 PCV^^
1615"DATA",1130580001.101,89,5)
1616NQF0038 NUM7 PCV
1617"DATA",1130580001.101,89,7)
1618NQF0038 NUM7 PCV^^^^^^205^192^11
1619"DATA",1130580001.101,90,0)
1620NQF0038 NUM8 HEP A^^
1621"DATA",1130580001.101,90,5)
1622NQF0038 NUM8 HEP A
1623"DATA",1130580001.101,90,7)
1624NQF0038 NUM8 HEP A^^^^^^208^192^11
1625"DATA",1130580001.101,91,0)
1626NQF0038 NUM9^^
1627"DATA",1130580001.101,91,5)
1628NQF0038 NUM9
1629"DATA",1130580001.101,91,7)
1630NQF0038 NUM9^^^^^^216^192^11
1631"DATA",1130580001.101,92,0)
1632NQF0038 NUM10^^
1633"DATA",1130580001.101,92,5)
1634NQF0038 NUM10
1635"DATA",1130580001.101,92,7)
1636NQF0038 NUM10^^^^^^331^192^11
1637"DATA",1130580001.101,93,0)
1638NQF0038 NUM11 COMBO5^^
1639"DATA",1130580001.101,93,5)
1640NQF0038 NUM11 COMBO5
1641"DATA",1130580001.101,93,7)
1642NQF0038 NUM11 COMBO5^^^^^^228^192^11
1643"DATA",1130580001.101,94,0)
1644NQF0038 NUM12 COMBO6^^
1645"DATA",1130580001.101,94,5)
1646NQF0038 NUM12 COMBO6
1647"DATA",1130580001.101,94,7)
1648NQF0038 NUM12 COMBO6^^^^^^231^192^11
1649"DATA",1130580001.101,95,0)
1650MU 2011 INP ADV DIRECTIVES^^
1651"DATA",1130580001.101,95,5)
1652Advance Directives
1653"DATA",1130580001.101,95,7)
1654^^^^
1655"DATA",1130580001.101,96,0)
1656MU 2011 INP CPOE^^
1657"DATA",1130580001.101,96,5)
1658CPOE for Medications
1659"DATA",1130580001.101,96,7)
1660^^^^
1661"DATA",1130580001.101,97,0)
1662MU 2011 INP MED RECON^^
1663"DATA",1130580001.101,97,5)
1664Medication Reconcilliation
1665"DATA",1130580001.101,97,7)
1666^^^^
1667"DATA",1130580001.101,98,0)
1668MU 2011 INP PROBLEM LIST^^
1669"DATA",1130580001.101,98,5)
1670Problem List
1671"DATA",1130580001.101,98,7)
1672^^^^
1673"DATA",1130580001.101,99,0)
1674MU 2011 INP VITAL SIGNS^^
1675"DATA",1130580001.101,99,5)
1676Record Vital Signs
1677"DATA",1130580001.101,99,7)
1678^^^^
1679"DATA",1130580001.101,100,0)
1680MU 2011 INP SMOKING STATUS^^
1681"DATA",1130580001.101,100,5)
1682Smoking Status
1683"DATA",1130580001.101,100,7)
1684^^^^
1685"DATA",1130580001.101,101,0)
1686MU 2011 INP MED LIST^^
1687"DATA",1130580001.101,101,5)
1688Active Medication List
1689"DATA",1130580001.101,101,7)
1690^^^^
1691"DATA",1130580001.101,102,0)
1692MU 2011 INP ALLERGY LIST^^
1693"DATA",1130580001.101,102,5)
1694Medication Allergy List
1695"DATA",1130580001.101,102,7)
1696^^^^
1697"DATA",1130580001.101,103,0)
1698MU 2011 INP DEMOGRAPHICS^^
1699"DATA",1130580001.101,103,5)
1700Record Demographics
1701"DATA",1130580001.101,103,7)
1702^^^^
1703"FIA",1130580001.101)
1704C0Q QUALITY MEASURE
1705"FIA",1130580001.101,0)
1706^C0Q(101,
1707"FIA",1130580001.101,0,0)
17081130580001.101I
1709"FIA",1130580001.101,0,1)
1710y^y^f^^y^^y^o^n
1711"FIA",1130580001.101,0,10)
1712
1713"FIA",1130580001.101,0,11)
1714
1715"FIA",1130580001.101,0,"RLRO")
1716
1717"FIA",1130580001.101,0,"VR")
17181.0^C0Q
1719"FIA",1130580001.101,1130580001.101)
17200
1721"FIA",1130580001.101,1130580001.111)
17220
1723"FRV1",1130580001.101,"23,7",7)
1724MU ED-1 NUMER RS
1725"FRV1",1130580001.101,"23,7",7,"F")
1726;PXRM(810.4,
1727"FRV1",1130580001.101,"23,7",8)
1728MU ED-1 DENOM RS
1729"FRV1",1130580001.101,"23,7",8,"F")
1730;PXRM(810.4,
1731"FRV1",1130580001.101,"24,7",7)
1732MU ED-2 NUMER RS
1733"FRV1",1130580001.101,"24,7",7,"F")
1734;PXRM(810.4,
1735"FRV1",1130580001.101,"24,7",8)
1736MU ED-2 DENOM RS
1737"FRV1",1130580001.101,"24,7",8,"F")
1738;PXRM(810.4,
1739"FRV1",1130580001.101,"25,7",7)
1740MU STK-2 NUMER RS
1741"FRV1",1130580001.101,"25,7",7,"F")
1742;PXRM(810.4,
1743"FRV1",1130580001.101,"25,7",8)
1744MU STK-2 DENOM RS
1745"FRV1",1130580001.101,"25,7",8,"F")
1746;PXRM(810.4,
1747"FRV1",1130580001.101,"26,7",7)
1748MU STK-3 NUMER RS
1749"FRV1",1130580001.101,"26,7",7,"F")
1750;PXRM(810.4,
1751"FRV1",1130580001.101,"26,7",8)
1752MU STK-3 DENOM RS
1753"FRV1",1130580001.101,"26,7",8,"F")
1754;PXRM(810.4,
1755"FRV1",1130580001.101,"27,7",7)
1756MU STK-4 NUMER RS
1757"FRV1",1130580001.101,"27,7",7,"F")
1758;PXRM(810.4,
1759"FRV1",1130580001.101,"27,7",8)
1760MU STK-4 DENOM RS
1761"FRV1",1130580001.101,"27,7",8,"F")
1762;PXRM(810.4,
1763"FRV1",1130580001.101,"28,7",7)
1764MU STK-5 NUMER RS
1765"FRV1",1130580001.101,"28,7",7,"F")
1766;PXRM(810.4,
1767"FRV1",1130580001.101,"28,7",8)
1768MU STK-5 DENOM RS
1769"FRV1",1130580001.101,"28,7",8,"F")
1770;PXRM(810.4,
1771"FRV1",1130580001.101,"29,7",7)
1772MU STK-6 NUMER RS
1773"FRV1",1130580001.101,"29,7",7,"F")
1774;PXRM(810.4,
1775"FRV1",1130580001.101,"29,7",8)
1776MU STK-6 DENOM RS
1777"FRV1",1130580001.101,"29,7",8,"F")
1778;PXRM(810.4,
1779"FRV1",1130580001.101,"30,7",7)
1780MU STK-8 NUMER RS
1781"FRV1",1130580001.101,"30,7",7,"F")
1782;PXRM(810.4,
1783"FRV1",1130580001.101,"30,7",8)
1784MU STK-8 DENOM RS
1785"FRV1",1130580001.101,"30,7",8,"F")
1786;PXRM(810.4,
1787"FRV1",1130580001.101,"31,7",7)
1788MU STK-10 NUMER RS
1789"FRV1",1130580001.101,"31,7",7,"F")
1790;PXRM(810.4,
1791"FRV1",1130580001.101,"31,7",8)
1792MU STK-10 DENOM RS
1793"FRV1",1130580001.101,"31,7",8,"F")
1794;PXRM(810.4,
1795"FRV1",1130580001.101,"32,7",7)
1796MU VTE-1 NUMER RS
1797"FRV1",1130580001.101,"32,7",7,"F")
1798;PXRM(810.4,
1799"FRV1",1130580001.101,"32,7",8)
1800MU VTE-1 DENOM RS
1801"FRV1",1130580001.101,"32,7",8,"F")
1802;PXRM(810.4,
1803"FRV1",1130580001.101,"33,7",7)
1804MU VTE-2 NUMER RS
1805"FRV1",1130580001.101,"33,7",7,"F")
1806;PXRM(810.4,
1807"FRV1",1130580001.101,"33,7",8)
1808MU VTE-2 DENOM RS
1809"FRV1",1130580001.101,"33,7",8,"F")
1810;PXRM(810.4,
1811"FRV1",1130580001.101,"34,7",7)
1812MU VTE-3 NUMER RS
1813"FRV1",1130580001.101,"34,7",7,"F")
1814;PXRM(810.4,
1815"FRV1",1130580001.101,"34,7",8)
1816MU VTE-3 DENOM RS
1817"FRV1",1130580001.101,"34,7",8,"F")
1818;PXRM(810.4,
1819"FRV1",1130580001.101,"35,7",7)
1820MU VTE-4 NUMER RS
1821"FRV1",1130580001.101,"35,7",7,"F")
1822;PXRM(810.4,
1823"FRV1",1130580001.101,"35,7",8)
1824MU VTE-4 DENOM RS
1825"FRV1",1130580001.101,"35,7",8,"F")
1826;PXRM(810.4,
1827"FRV1",1130580001.101,"36,7",7)
1828MU VTE-5 NUMER RS
1829"FRV1",1130580001.101,"36,7",7,"F")
1830;PXRM(810.4,
1831"FRV1",1130580001.101,"36,7",8)
1832MU VTE-5 DENOM RS
1833"FRV1",1130580001.101,"36,7",8,"F")
1834;PXRM(810.4,
1835"FRV1",1130580001.101,"37,7",7)
1836MU VTE-6 NUMER RS
1837"FRV1",1130580001.101,"37,7",7,"F")
1838;PXRM(810.4,
1839"FRV1",1130580001.101,"37,7",8)
1840MU VTE-6 DENOM RS
1841"FRV1",1130580001.101,"37,7",8,"F")
1842;PXRM(810.4,
1843"FRV1",1130580001.101,"39,7",7)
1844MU NQF0421 BMI NUM ALL RS
1845"FRV1",1130580001.101,"39,7",7,"F")
1846;PXRM(810.4,
1847"FRV1",1130580001.101,"39,7",8)
1848MU NQF0421 BMI DENOM ALL RS
1849"FRV1",1130580001.101,"39,7",8,"F")
1850;PXRM(810.4,
1851"FRV1",1130580001.101,"39,7",9)
1852MU NQF0421 ADULT BMI
1853"FRV1",1130580001.101,"39,7",9,"F")
1854;PXRM(810.2,
1855"FRV1",1130580001.101,"40,7",7)
1856MU NQF0013 HTN NUMER2 RS
1857"FRV1",1130580001.101,"40,7",7,"F")
1858;PXRM(810.4,
1859"FRV1",1130580001.101,"40,7",8)
1860MU NQF0013 HTN DENOM2 RS
1861"FRV1",1130580001.101,"40,7",8,"F")
1862;PXRM(810.4,
1863"FRV1",1130580001.101,"41,7",7)
1864MU NQF0028A TOBACCO SCREEN NUM RS
1865"FRV1",1130580001.101,"41,7",7,"F")
1866;PXRM(810.4,
1867"FRV1",1130580001.101,"41,7",8)
1868MU NQF0028B TOBACCO INTERV DENOM RS
1869"FRV1",1130580001.101,"41,7",8,"F")
1870;PXRM(810.4,
1871"FRV1",1130580001.101,"42,7",7)
1872MU NQF0041 FLU RS
1873"FRV1",1130580001.101,"42,7",7,"F")
1874;PXRM(810.4,
1875"FRV1",1130580001.101,"42,7",8)
1876MU NQF0041 FLU DENOM RS
1877"FRV1",1130580001.101,"42,7",8,"F")
1878;PXRM(810.4,
1879"FRV1",1130580001.101,"43,7",7)
1880MU NQF0024 BMI 2-17YR NUM RS
1881"FRV1",1130580001.101,"43,7",7,"F")
1882;PXRM(810.4,
1883"FRV1",1130580001.101,"43,7",8)
1884MU NQF0024 BMI 2-17YRS DEM RS
1885"FRV1",1130580001.101,"43,7",8,"F")
1886;PXRM(810.4,
1887"FRV1",1130580001.101,"45,7",7)
1888MU NQF0059 HBA1C NUM RS
1889"FRV1",1130580001.101,"45,7",7,"F")
1890;PXRM(810.4,
1891"FRV1",1130580001.101,"45,7",8)
1892MU NQF0059 DM DENOM-ALL RS
1893"FRV1",1130580001.101,"45,7",8,"F")
1894;PXRM(810.4,
1895"FRV1",1130580001.101,"46,7",7)
1896MU NQF0064 NUM LDL RS
1897"FRV1",1130580001.101,"46,7",7,"F")
1898;PXRM(810.4,
1899"FRV1",1130580001.101,"46,7",8)
1900MU NQF0059 DM DENOM-ALL RS
1901"FRV1",1130580001.101,"46,7",8,"F")
1902;PXRM(810.4,
1903"FRV1",1130580001.101,"47,7",7)
1904MU NQF0061 NUM DM BP<140/90 RS
1905"FRV1",1130580001.101,"47,7",7,"F")
1906;PXRM(810.4,
1907"FRV1",1130580001.101,"47,7",8)
1908MU NQF0059 DM DENOM-ALL RS
1909"FRV1",1130580001.101,"47,7",8,"F")
1910;PXRM(810.4,
1911"FRV1",1130580001.101,"81,7",7)
1912MU NQF0028B TOBACCO INTERV NUM2 RS
1913"FRV1",1130580001.101,"81,7",7,"F")
1914;PXRM(810.4,
1915"FRV1",1130580001.101,"81,7",8)
1916MU NQF0028B TOBACCO INTERV DENOM RS
1917"FRV1",1130580001.101,"81,7",8,"F")
1918;PXRM(810.4,
1919"FRV1",1130580001.101,"83,7",7)
1920MU NQF0038 NUM1 DPT RS
1921"FRV1",1130580001.101,"83,7",7,"F")
1922;PXRM(810.4,
1923"FRV1",1130580001.101,"83,7",8)
1924MU NQF0038 DENOM RS
1925"FRV1",1130580001.101,"83,7",8,"F")
1926;PXRM(810.4,
1927"FRV1",1130580001.101,"83,7",9)
1928MU NQF0038 CHILDREN'S IMMUNIZATIONS
1929"FRV1",1130580001.101,"83,7",9,"F")
1930;PXRM(810.2,
1931"FRV1",1130580001.101,"84,7",7)
1932MU NQF0038 NUM2 IPV RS
1933"FRV1",1130580001.101,"84,7",7,"F")
1934;PXRM(810.4,
1935"FRV1",1130580001.101,"84,7",8)
1936MU NQF0038 DENOM RS
1937"FRV1",1130580001.101,"84,7",8,"F")
1938;PXRM(810.4,
1939"FRV1",1130580001.101,"84,7",9)
1940MU NQF0038 CHILDREN'S IMMUNIZATIONS
1941"FRV1",1130580001.101,"84,7",9,"F")
1942;PXRM(810.2,
1943"FRV1",1130580001.101,"85,7",7)
1944MU NQF0038 NUM3-ALL RS
1945"FRV1",1130580001.101,"85,7",7,"F")
1946;PXRM(810.4,
1947"FRV1",1130580001.101,"85,7",8)
1948MU NQF0038 DENOM RS
1949"FRV1",1130580001.101,"85,7",8,"F")
1950;PXRM(810.4,
1951"FRV1",1130580001.101,"85,7",9)
1952MU NQF0038 CHILDREN'S IMMUNIZATIONS
1953"FRV1",1130580001.101,"85,7",9,"F")
1954;PXRM(810.2,
1955"FRV1",1130580001.101,"86,7",7)
1956MU NQF0038 NUM4 HIB RS
1957"FRV1",1130580001.101,"86,7",7,"F")
1958;PXRM(810.4,
1959"FRV1",1130580001.101,"86,7",8)
1960MU NQF0038 DENOM RS
1961"FRV1",1130580001.101,"86,7",8,"F")
1962;PXRM(810.4,
1963"FRV1",1130580001.101,"86,7",9)
1964MU NQF0038 CHILDREN'S IMMUNIZATIONS
1965"FRV1",1130580001.101,"86,7",9,"F")
1966;PXRM(810.2,
1967"FRV1",1130580001.101,"87,7",7)
1968MU NQF0038 NUM5 RS
1969"FRV1",1130580001.101,"87,7",7,"F")
1970;PXRM(810.4,
1971"FRV1",1130580001.101,"87,7",8)
1972MU NQF0038 DENOM RS
1973"FRV1",1130580001.101,"87,7",8,"F")
1974;PXRM(810.4,
1975"FRV1",1130580001.101,"87,7",9)
1976MU NQF0038 CHILDREN'S IMMUNIZATIONS
1977"FRV1",1130580001.101,"87,7",9,"F")
1978;PXRM(810.2,
1979"FRV1",1130580001.101,"88,7",7)
1980MU NQF0038 NUM6 VZV RS
1981"FRV1",1130580001.101,"88,7",7,"F")
1982;PXRM(810.4,
1983"FRV1",1130580001.101,"88,7",8)
1984MU NQF0038 DENOM RS
1985"FRV1",1130580001.101,"88,7",8,"F")
1986;PXRM(810.4,
1987"FRV1",1130580001.101,"88,7",9)
1988MU NQF0038 CHILDREN'S IMMUNIZATIONS
1989"FRV1",1130580001.101,"88,7",9,"F")
1990;PXRM(810.2,
1991"FRV1",1130580001.101,"89,7",7)
1992MU NQF0038 NUM7 PCV RS
1993"FRV1",1130580001.101,"89,7",7,"F")
1994;PXRM(810.4,
1995"FRV1",1130580001.101,"89,7",8)
1996MU NQF0038 DENOM RS
1997"FRV1",1130580001.101,"89,7",8,"F")
1998;PXRM(810.4,
1999"FRV1",1130580001.101,"89,7",9)
2000MU NQF0038 CHILDREN'S IMMUNIZATIONS
2001"FRV1",1130580001.101,"89,7",9,"F")
2002;PXRM(810.2,
2003"FRV1",1130580001.101,"90,7",7)
2004MU NQF0038 NUM8 HEP A RS
2005"FRV1",1130580001.101,"90,7",7,"F")
2006;PXRM(810.4,
2007"FRV1",1130580001.101,"90,7",8)
2008MU NQF0038 DENOM RS
2009"FRV1",1130580001.101,"90,7",8,"F")
2010;PXRM(810.4,
2011"FRV1",1130580001.101,"90,7",9)
2012MU NQF0038 CHILDREN'S IMMUNIZATIONS
2013"FRV1",1130580001.101,"90,7",9,"F")
2014;PXRM(810.2,
2015"FRV1",1130580001.101,"91,7",7)
2016MU NQF0038 NUM9 RV RS
2017"FRV1",1130580001.101,"91,7",7,"F")
2018;PXRM(810.4,
2019"FRV1",1130580001.101,"91,7",8)
2020MU NQF0038 DENOM RS
2021"FRV1",1130580001.101,"91,7",8,"F")
2022;PXRM(810.4,
2023"FRV1",1130580001.101,"91,7",9)
2024MU NQF0038 CHILDREN'S IMMUNIZATIONS
2025"FRV1",1130580001.101,"91,7",9,"F")
2026;PXRM(810.2,
2027"FRV1",1130580001.101,"92,7",7)
2028MU NQF0038 NUM10 INFLUENZA RS
2029"FRV1",1130580001.101,"92,7",7,"F")
2030;PXRM(810.4,
2031"FRV1",1130580001.101,"92,7",8)
2032MU NQF0038 DENOM RS
2033"FRV1",1130580001.101,"92,7",8,"F")
2034;PXRM(810.4,
2035"FRV1",1130580001.101,"92,7",9)
2036MU NQF0038 CHILDREN'S IMMUNIZATIONS
2037"FRV1",1130580001.101,"92,7",9,"F")
2038;PXRM(810.2,
2039"FRV1",1130580001.101,"93,7",7)
2040MU NQF0038 NUM11 COMBO5 RS
2041"FRV1",1130580001.101,"93,7",7,"F")
2042;PXRM(810.4,
2043"FRV1",1130580001.101,"93,7",8)
2044MU NQF0038 DENOM RS
2045"FRV1",1130580001.101,"93,7",8,"F")
2046;PXRM(810.4,
2047"FRV1",1130580001.101,"93,7",9)
2048MU NQF0038 CHILDREN'S IMMUNIZATIONS
2049"FRV1",1130580001.101,"93,7",9,"F")
2050;PXRM(810.2,
2051"FRV1",1130580001.101,"94,7",7)
2052MU NQF0038 NUM12 COMBO6 RS
2053"FRV1",1130580001.101,"94,7",7,"F")
2054;PXRM(810.4,
2055"FRV1",1130580001.101,"94,7",8)
2056MU NQF0038 DENOM RS
2057"FRV1",1130580001.101,"94,7",8,"F")
2058;PXRM(810.4,
2059"FRV1",1130580001.101,"94,7",9)
2060MU NQF0038 CHILDREN'S IMMUNIZATIONS
2061"FRV1",1130580001.101,"94,7",9,"F")
2062;PXRM(810.2,
2063"FRV1K",1130580001.101,"23,7",7)
2064B
2065"FRV1K",1130580001.101,"23,7",7,1)
2066MU ED-1 NUMER RS
2067"FRV1K",1130580001.101,"23,7",8)
2068B
2069"FRV1K",1130580001.101,"23,7",8,1)
2070MU ED-1 DENOM RS
2071"FRV1K",1130580001.101,"24,7",7)
2072B
2073"FRV1K",1130580001.101,"24,7",7,1)
2074MU ED-2 NUMER RS
2075"FRV1K",1130580001.101,"24,7",8)
2076B
2077"FRV1K",1130580001.101,"24,7",8,1)
2078MU ED-2 DENOM RS
2079"FRV1K",1130580001.101,"25,7",7)
2080B
2081"FRV1K",1130580001.101,"25,7",7,1)
2082MU STK-2 NUMER RS
2083"FRV1K",1130580001.101,"25,7",8)
2084B
2085"FRV1K",1130580001.101,"25,7",8,1)
2086MU STK-2 DENOM RS
2087"FRV1K",1130580001.101,"26,7",7)
2088B
2089"FRV1K",1130580001.101,"26,7",7,1)
2090MU STK-3 NUMER RS
2091"FRV1K",1130580001.101,"26,7",8)
2092B
2093"FRV1K",1130580001.101,"26,7",8,1)
2094MU STK-3 DENOM RS
2095"FRV1K",1130580001.101,"27,7",7)
2096B
2097"FRV1K",1130580001.101,"27,7",7,1)
2098MU STK-4 NUMER RS
2099"FRV1K",1130580001.101,"27,7",8)
2100B
2101"FRV1K",1130580001.101,"27,7",8,1)
2102MU STK-4 DENOM RS
2103"FRV1K",1130580001.101,"28,7",7)
2104B
2105"FRV1K",1130580001.101,"28,7",7,1)
2106MU STK-5 NUMER RS
2107"FRV1K",1130580001.101,"28,7",8)
2108B
2109"FRV1K",1130580001.101,"28,7",8,1)
2110MU STK-5 DENOM RS
2111"FRV1K",1130580001.101,"29,7",7)
2112B
2113"FRV1K",1130580001.101,"29,7",7,1)
2114MU STK-6 NUMER RS
2115"FRV1K",1130580001.101,"29,7",8)
2116B
2117"FRV1K",1130580001.101,"29,7",8,1)
2118MU STK-6 DENOM RS
2119"FRV1K",1130580001.101,"30,7",7)
2120B
2121"FRV1K",1130580001.101,"30,7",7,1)
2122MU STK-8 NUMER RS
2123"FRV1K",1130580001.101,"30,7",8)
2124B
2125"FRV1K",1130580001.101,"30,7",8,1)
2126MU STK-8 DENOM RS
2127"FRV1K",1130580001.101,"31,7",7)
2128B
2129"FRV1K",1130580001.101,"31,7",7,1)
2130MU STK-10 NUMER RS
2131"FRV1K",1130580001.101,"31,7",8)
2132B
2133"FRV1K",1130580001.101,"31,7",8,1)
2134MU STK-10 DENOM RS
2135"FRV1K",1130580001.101,"32,7",7)
2136B
2137"FRV1K",1130580001.101,"32,7",7,1)
2138MU VTE-1 NUMER RS
2139"FRV1K",1130580001.101,"32,7",8)
2140B
2141"FRV1K",1130580001.101,"32,7",8,1)
2142MU VTE-1 DENOM RS
2143"FRV1K",1130580001.101,"33,7",7)
2144B
2145"FRV1K",1130580001.101,"33,7",7,1)
2146MU VTE-2 NUMER RS
2147"FRV1K",1130580001.101,"33,7",8)
2148B
2149"FRV1K",1130580001.101,"33,7",8,1)
2150MU VTE-2 DENOM RS
2151"FRV1K",1130580001.101,"34,7",7)
2152B
2153"FRV1K",1130580001.101,"34,7",7,1)
2154MU VTE-3 NUMER RS
2155"FRV1K",1130580001.101,"34,7",8)
2156B
2157"FRV1K",1130580001.101,"34,7",8,1)
2158MU VTE-3 DENOM RS
2159"FRV1K",1130580001.101,"35,7",7)
2160B
2161"FRV1K",1130580001.101,"35,7",7,1)
2162MU VTE-4 NUMER RS
2163"FRV1K",1130580001.101,"35,7",8)
2164B
2165"FRV1K",1130580001.101,"35,7",8,1)
2166MU VTE-4 DENOM RS
2167"FRV1K",1130580001.101,"36,7",7)
2168B
2169"FRV1K",1130580001.101,"36,7",7,1)
2170MU VTE-5 NUMER RS
2171"FRV1K",1130580001.101,"36,7",8)
2172B
2173"FRV1K",1130580001.101,"36,7",8,1)
2174MU VTE-5 DENOM RS
2175"FRV1K",1130580001.101,"37,7",7)
2176B
2177"FRV1K",1130580001.101,"37,7",7,1)
2178MU VTE-6 NUMER RS
2179"FRV1K",1130580001.101,"37,7",8)
2180B
2181"FRV1K",1130580001.101,"37,7",8,1)
2182MU VTE-6 DENOM RS
2183"FRV1K",1130580001.101,"39,7",7)
2184B
2185"FRV1K",1130580001.101,"39,7",7,1)
2186MU NQF0421 BMI NUM ALL RS
2187"FRV1K",1130580001.101,"39,7",8)
2188B
2189"FRV1K",1130580001.101,"39,7",8,1)
2190MU NQF0421 BMI DENOM ALL RS
2191"FRV1K",1130580001.101,"39,7",9)
2192B
2193"FRV1K",1130580001.101,"39,7",9,1)
2194MU NQF0421 ADULT BMI
2195"FRV1K",1130580001.101,"40,7",7)
2196B
2197"FRV1K",1130580001.101,"40,7",7,1)
2198MU NQF0013 HTN NUMER2 RS
2199"FRV1K",1130580001.101,"40,7",8)
2200B
2201"FRV1K",1130580001.101,"40,7",8,1)
2202MU NQF0013 HTN DENOM2 RS
2203"FRV1K",1130580001.101,"41,7",7)
2204B
2205"FRV1K",1130580001.101,"41,7",7,1)
2206MU NQF0028A TOBACCO SCREEN NUM RS
2207"FRV1K",1130580001.101,"41,7",8)
2208B
2209"FRV1K",1130580001.101,"41,7",8,1)
2210MU NQF0028B TOBACCO INTERV DENOM RS
2211"FRV1K",1130580001.101,"42,7",7)
2212B
2213"FRV1K",1130580001.101,"42,7",7,1)
2214MU NQF0041 FLU RS
2215"FRV1K",1130580001.101,"42,7",8)
2216B
2217"FRV1K",1130580001.101,"42,7",8,1)
2218MU NQF0041 FLU DENOM RS
2219"FRV1K",1130580001.101,"43,7",7)
2220B
2221"FRV1K",1130580001.101,"43,7",7,1)
2222MU NQF0024 BMI 2-17YR NUM RS
2223"FRV1K",1130580001.101,"43,7",8)
2224B
2225"FRV1K",1130580001.101,"43,7",8,1)
2226MU NQF0024 BMI 2-17YRS DEM RS
2227"FRV1K",1130580001.101,"45,7",7)
2228B
2229"FRV1K",1130580001.101,"45,7",7,1)
2230MU NQF0059 HBA1C NUM RS
2231"FRV1K",1130580001.101,"45,7",8)
2232B
2233"FRV1K",1130580001.101,"45,7",8,1)
2234MU NQF0059 DM DENOM-ALL RS
2235"FRV1K",1130580001.101,"46,7",7)
2236B
2237"FRV1K",1130580001.101,"46,7",7,1)
2238MU NQF0064 NUM LDL RS
2239"FRV1K",1130580001.101,"46,7",8)
2240B
2241"FRV1K",1130580001.101,"46,7",8,1)
2242MU NQF0059 DM DENOM-ALL RS
2243"FRV1K",1130580001.101,"47,7",7)
2244B
2245"FRV1K",1130580001.101,"47,7",7,1)
2246MU NQF0061 NUM DM BP<140/90 RS
2247"FRV1K",1130580001.101,"47,7",8)
2248B
2249"FRV1K",1130580001.101,"47,7",8,1)
2250MU NQF0059 DM DENOM-ALL RS
2251"FRV1K",1130580001.101,"81,7",7)
2252B
2253"FRV1K",1130580001.101,"81,7",7,1)
2254MU NQF0028B TOBACCO INTERV NUM2 RS
2255"FRV1K",1130580001.101,"81,7",8)
2256B
2257"FRV1K",1130580001.101,"81,7",8,1)
2258MU NQF0028B TOBACCO INTERV DENOM RS
2259"FRV1K",1130580001.101,"83,7",7)
2260B
2261"FRV1K",1130580001.101,"83,7",7,1)
2262MU NQF0038 NUM1 DPT RS
2263"FRV1K",1130580001.101,"83,7",8)
2264B
2265"FRV1K",1130580001.101,"83,7",8,1)
2266MU NQF0038 DENOM RS
2267"FRV1K",1130580001.101,"83,7",9)
2268B
2269"FRV1K",1130580001.101,"83,7",9,1)
2270MU NQF0038 CHILDREN'S IMMUNIZATIONS
2271"FRV1K",1130580001.101,"84,7",7)
2272B
2273"FRV1K",1130580001.101,"84,7",7,1)
2274MU NQF0038 NUM2 IPV RS
2275"FRV1K",1130580001.101,"84,7",8)
2276B
2277"FRV1K",1130580001.101,"84,7",8,1)
2278MU NQF0038 DENOM RS
2279"FRV1K",1130580001.101,"84,7",9)
2280B
2281"FRV1K",1130580001.101,"84,7",9,1)
2282MU NQF0038 CHILDREN'S IMMUNIZATIONS
2283"FRV1K",1130580001.101,"85,7",7)
2284B
2285"FRV1K",1130580001.101,"85,7",7,1)
2286MU NQF0038 NUM3-ALL RS
2287"FRV1K",1130580001.101,"85,7",8)
2288B
2289"FRV1K",1130580001.101,"85,7",8,1)
2290MU NQF0038 DENOM RS
2291"FRV1K",1130580001.101,"85,7",9)
2292B
2293"FRV1K",1130580001.101,"85,7",9,1)
2294MU NQF0038 CHILDREN'S IMMUNIZATIONS
2295"FRV1K",1130580001.101,"86,7",7)
2296B
2297"FRV1K",1130580001.101,"86,7",7,1)
2298MU NQF0038 NUM4 HIB RS
2299"FRV1K",1130580001.101,"86,7",8)
2300B
2301"FRV1K",1130580001.101,"86,7",8,1)
2302MU NQF0038 DENOM RS
2303"FRV1K",1130580001.101,"86,7",9)
2304B
2305"FRV1K",1130580001.101,"86,7",9,1)
2306MU NQF0038 CHILDREN'S IMMUNIZATIONS
2307"FRV1K",1130580001.101,"87,7",7)
2308B
2309"FRV1K",1130580001.101,"87,7",7,1)
2310MU NQF0038 NUM5 RS
2311"FRV1K",1130580001.101,"87,7",8)
2312B
2313"FRV1K",1130580001.101,"87,7",8,1)
2314MU NQF0038 DENOM RS
2315"FRV1K",1130580001.101,"87,7",9)
2316B
2317"FRV1K",1130580001.101,"87,7",9,1)
2318MU NQF0038 CHILDREN'S IMMUNIZATIONS
2319"FRV1K",1130580001.101,"88,7",7)
2320B
2321"FRV1K",1130580001.101,"88,7",7,1)
2322MU NQF0038 NUM6 VZV RS
2323"FRV1K",1130580001.101,"88,7",8)
2324B
2325"FRV1K",1130580001.101,"88,7",8,1)
2326MU NQF0038 DENOM RS
2327"FRV1K",1130580001.101,"88,7",9)
2328B
2329"FRV1K",1130580001.101,"88,7",9,1)
2330MU NQF0038 CHILDREN'S IMMUNIZATIONS
2331"FRV1K",1130580001.101,"89,7",7)
2332B
2333"FRV1K",1130580001.101,"89,7",7,1)
2334MU NQF0038 NUM7 PCV RS
2335"FRV1K",1130580001.101,"89,7",8)
2336B
2337"FRV1K",1130580001.101,"89,7",8,1)
2338MU NQF0038 DENOM RS
2339"FRV1K",1130580001.101,"89,7",9)
2340B
2341"FRV1K",1130580001.101,"89,7",9,1)
2342MU NQF0038 CHILDREN'S IMMUNIZATIONS
2343"FRV1K",1130580001.101,"90,7",7)
2344B
2345"FRV1K",1130580001.101,"90,7",7,1)
2346MU NQF0038 NUM8 HEP A RS
2347"FRV1K",1130580001.101,"90,7",8)
2348B
2349"FRV1K",1130580001.101,"90,7",8,1)
2350MU NQF0038 DENOM RS
2351"FRV1K",1130580001.101,"90,7",9)
2352B
2353"FRV1K",1130580001.101,"90,7",9,1)
2354MU NQF0038 CHILDREN'S IMMUNIZATIONS
2355"FRV1K",1130580001.101,"91,7",7)
2356B
2357"FRV1K",1130580001.101,"91,7",7,1)
2358MU NQF0038 NUM9 RV RS
2359"FRV1K",1130580001.101,"91,7",8)
2360B
2361"FRV1K",1130580001.101,"91,7",8,1)
2362MU NQF0038 DENOM RS
2363"FRV1K",1130580001.101,"91,7",9)
2364B
2365"FRV1K",1130580001.101,"91,7",9,1)
2366MU NQF0038 CHILDREN'S IMMUNIZATIONS
2367"FRV1K",1130580001.101,"92,7",7)
2368B
2369"FRV1K",1130580001.101,"92,7",7,1)
2370MU NQF0038 NUM10 INFLUENZA RS
2371"FRV1K",1130580001.101,"92,7",8)
2372B
2373"FRV1K",1130580001.101,"92,7",8,1)
2374MU NQF0038 DENOM RS
2375"FRV1K",1130580001.101,"92,7",9)
2376B
2377"FRV1K",1130580001.101,"92,7",9,1)
2378MU NQF0038 CHILDREN'S IMMUNIZATIONS
2379"FRV1K",1130580001.101,"93,7",7)
2380B
2381"FRV1K",1130580001.101,"93,7",7,1)
2382MU NQF0038 NUM11 COMBO5 RS
2383"FRV1K",1130580001.101,"93,7",8)
2384B
2385"FRV1K",1130580001.101,"93,7",8,1)
2386MU NQF0038 DENOM RS
2387"FRV1K",1130580001.101,"93,7",9)
2388B
2389"FRV1K",1130580001.101,"93,7",9,1)
2390MU NQF0038 CHILDREN'S IMMUNIZATIONS
2391"FRV1K",1130580001.101,"94,7",7)
2392B
2393"FRV1K",1130580001.101,"94,7",7,1)
2394MU NQF0038 NUM12 COMBO6 RS
2395"FRV1K",1130580001.101,"94,7",8)
2396B
2397"FRV1K",1130580001.101,"94,7",8,1)
2398MU NQF0038 DENOM RS
2399"FRV1K",1130580001.101,"94,7",9)
2400B
2401"FRV1K",1130580001.101,"94,7",9,1)
2402MU NQF0038 CHILDREN'S IMMUNIZATIONS
2403"IX",1130580001.101,1130580001.101,"MU",0)
24041130580001.101^MU^MEANINGFUL USE YEAR KEY^R^^F^IR^I^1130580001.101^^^^^LS
2405"IX",1130580001.101,1130580001.101,"MU",1)
2406S ^C0Q(101,"MU",$E(X,1,30),DA)=""
2407"IX",1130580001.101,1130580001.101,"MU",2)
2408K ^C0Q(101,"MU",$E(X,1,30),DA)
2409"IX",1130580001.101,1130580001.101,"MU",2.5)
2410K ^C0Q(101,"MU")
2411"IX",1130580001.101,1130580001.101,"MU",11.1,0)
2412^.114IA^1^1
2413"IX",1130580001.101,1130580001.101,"MU",11.1,1,0)
24141^F^1130580001.101^.3^30^1^F
2415"MBREQ")
24160
2417"PGL",1130580001.101,0,2,1)
2418NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q
2419"PGL",1130580001.101,0,3,2)
2420DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q
2421"PGL",1130580001.101,7,2,1.1)
2422ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q
2423"PGL",1130580001.101,7,3,2.1)
2424ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q
2425"PGL",1130580001.101,7,4,1.5)
2426NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q
2427"PGL",1130580001.101,7,5,1.51)
2428ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q
2429"PGL",1130580001.101,7,7,1.2)
2430NUMERATOR RULE SET^*P810.4'^PXRM(810.4,^7;7^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
2431"PGL",1130580001.101,7,8,2.2)
2432DENOMINATOR RULE SET^*P810.4'^PXRM(810.4,^7;8^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
2433"PGL",1130580001.101,7,9,2.5)
2434EXTRACT DEFINITION^P810.2'^PXRM(810.2,^7;9^Q
2435"PKG",215,-1)
24361^1
2437"PKG",215,0)
2438QUALITY MEASURES^C0Q^Tracks and Prints Quality Measures
2439"PKG",215,20,0)
2440^9.402P^^
2441"PKG",215,22,0)
2442^9.49I^1^1
2443"PKG",215,22,1,0)
24441.0^3120713^3120702^8
2445"PKG",215,22,1,"PAH",1,0)
24463^3120727
2447"PKG",215,22,1,"PAH",1,1,0)
2448^^5^5^3120727
2449"PKG",215,22,1,"PAH",1,1,1,0)
2450Created by Sam Habiel on July 13th 2012 for distribution with WorldVistA
2451"PKG",215,22,1,"PAH",1,1,2,0)
24522.0.
2453"PKG",215,22,1,"PAH",1,1,3,0)
2454
2455"PKG",215,22,1,"PAH",1,1,4,0)
2456Contains updated C0Q QUALITY MEASURES file containing the appropriate
2457"PKG",215,22,1,"PAH",1,1,5,0)
2458rule sets to use after each measure.
2459"QUES","XPF1",0)
2460Y
2461"QUES","XPF1","??")
2462^D REP^XPDH
2463"QUES","XPF1","A")
2464Shall I write over your |FLAG| File
2465"QUES","XPF1","B")
2466YES
2467"QUES","XPF1","M")
2468D XPF1^XPDIQ
2469"QUES","XPF2",0)
2470Y
2471"QUES","XPF2","??")
2472^D DTA^XPDH
2473"QUES","XPF2","A")
2474Want my data |FLAG| yours
2475"QUES","XPF2","B")
2476YES
2477"QUES","XPF2","M")
2478D XPF2^XPDIQ
2479"QUES","XPI1",0)
2480YO
2481"QUES","XPI1","??")
2482^D INHIBIT^XPDH
2483"QUES","XPI1","A")
2484Want KIDS to INHIBIT LOGONs during the install
2485"QUES","XPI1","B")
2486NO
2487"QUES","XPI1","M")
2488D XPI1^XPDIQ
2489"QUES","XPM1",0)
2490PO^VA(200,:EM
2491"QUES","XPM1","??")
2492^D MG^XPDH
2493"QUES","XPM1","A")
2494Enter the Coordinator for Mail Group '|FLAG|'
2495"QUES","XPM1","B")
2496
2497"QUES","XPM1","M")
2498D XPM1^XPDIQ
2499"QUES","XPO1",0)
2500Y
2501"QUES","XPO1","??")
2502^D MENU^XPDH
2503"QUES","XPO1","A")
2504Want KIDS to Rebuild Menu Trees Upon Completion of Install
2505"QUES","XPO1","B")
2506NO
2507"QUES","XPO1","M")
2508D XPO1^XPDIQ
2509"QUES","XPZ1",0)
2510Y
2511"QUES","XPZ1","??")
2512^D OPT^XPDH
2513"QUES","XPZ1","A")
2514Want to DISABLE Scheduled Options, Menu Options, and Protocols
2515"QUES","XPZ1","B")
2516NO
2517"QUES","XPZ1","M")
2518D XPZ1^XPDIQ
2519"QUES","XPZ2",0)
2520Y
2521"QUES","XPZ2","??")
2522^D RTN^XPDH
2523"QUES","XPZ2","A")
2524Want to MOVE routines to other CPUs
2525"QUES","XPZ2","B")
2526NO
2527"QUES","XPZ2","M")
2528D XPZ2^XPDIQ
2529"SEC","^DD",1130580001.101,1130580001.101,3.1,9)
2530
2531"SEC","^DIC",1130580001.101,1130580001.101,0,"AUDIT")
2532@
2533"SEC","^DIC",1130580001.101,1130580001.101,0,"DD")
2534@
2535"SEC","^DIC",1130580001.101,1130580001.101,0,"DEL")
2536@
2537"SEC","^DIC",1130580001.101,1130580001.101,0,"LAYGO")
2538@
2539"SEC","^DIC",1130580001.101,1130580001.101,0,"RD")
2540@
2541"SEC","^DIC",1130580001.101,1130580001.101,0,"WR")
2542@
2543"VER")
25448.0^22.0
2545"^DD",1130580001.101,1130580001.101,0)
2546FIELD^^2.5^18
2547"^DD",1130580001.101,1130580001.101,0,"DDA")
2548N
2549"^DD",1130580001.101,1130580001.101,0,"DT")
25503120726
2551"^DD",1130580001.101,1130580001.101,0,"ID",.7)
2552W:$D(^(5)) " ",$P(^(5),U,1)
2553"^DD",1130580001.101,1130580001.101,0,"IX","B",1130580001.101,.01)
2554
2555"^DD",1130580001.101,1130580001.101,0,"NM","C0Q QUALITY MEASURE")
2556
2557"^DD",1130580001.101,1130580001.101,0,"PT",1130580001.2011,.01)
2558
2559"^DD",1130580001.101,1130580001.101,0,"VRPK")
2560QUALITY MEASURES
2561"^DD",1130580001.101,1130580001.101,.01,0)
2562NAME^RF^^0;1^K:$L(X)>30!($L(X)<1)!'(X'?1P.E) X
2563"^DD",1130580001.101,1130580001.101,.01,.1)
2564MEASURE NAME
2565"^DD",1130580001.101,1130580001.101,.01,1,0)
2566^.1
2567"^DD",1130580001.101,1130580001.101,.01,1,1,0)
25681130580001.101^B
2569"^DD",1130580001.101,1130580001.101,.01,1,1,1)
2570S ^C0Q(101,"B",$E(X,1,30),DA)=""
2571"^DD",1130580001.101,1130580001.101,.01,1,1,2)
2572K ^C0Q(101,"B",$E(X,1,30),DA)
2573"^DD",1130580001.101,1130580001.101,.01,3)
2574Answer must be 1-30 characters in length
2575"^DD",1130580001.101,1130580001.101,.01,"DT")
25763101012
2577"^DD",1130580001.101,1130580001.101,.3,0)
2578MU YEAR KEY^F^^7;6^K:$L(X)>30!($L(X)<1) X
2579"^DD",1130580001.101,1130580001.101,.3,.1)
2580MEANINGFUL USE YEAR KEY
2581"^DD",1130580001.101,1130580001.101,.3,3)
2582Answer must be 1-30 characters in length.
2583"^DD",1130580001.101,1130580001.101,.3,"DT")
25843111201
2585"^DD",1130580001.101,1130580001.101,.5,0)
2586TITLE^F^^1;1^K:$L(X)>240!($L(X)<3) X
2587"^DD",1130580001.101,1130580001.101,.5,.1)
2588MEASURE TITLE
2589"^DD",1130580001.101,1130580001.101,.5,3)
2590Answer must be 3-240 characters in length
2591"^DD",1130580001.101,1130580001.101,.5,"DT")
25923110430
2593"^DD",1130580001.101,1130580001.101,.61,0)
2594VERY LONG DESCRIPTION^1130580001.111^^6;0
2595"^DD",1130580001.101,1130580001.101,.7,0)
2596DISPLAY NAME^F^^5;1^K:$L(X)>240!($L(X)<3) X
2597"^DD",1130580001.101,1130580001.101,.7,.1)
2598QRDA DISPLAY NAME
2599"^DD",1130580001.101,1130580001.101,.7,3)
2600Answer must be 3-240 characters in length
2601"^DD",1130580001.101,1130580001.101,.7,"DT")
26023101012
2603"^DD",1130580001.101,1130580001.101,.8,0)
2604REPORTING NAME^F^^7;1^K:$L(X)>30!($L(X)<3) X
2605"^DD",1130580001.101,1130580001.101,.8,.1)
2606REPORTING MEASURE NAME
2607"^DD",1130580001.101,1130580001.101,.8,3)
2608Answer must be 3-30 characters in length
2609"^DD",1130580001.101,1130580001.101,.8,"DT")
26103110615
2611"^DD",1130580001.101,1130580001.101,1,0)
2612NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q
2613"^DD",1130580001.101,1130580001.101,1,.1)
2614MEASURE NUMERATOR PATIENT LIST
2615"^DD",1130580001.101,1130580001.101,1,"DT")
26163101012
2617"^DD",1130580001.101,1130580001.101,1.1,0)
2618ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q
2619"^DD",1130580001.101,1130580001.101,1.1,"DT")
26203110805
2621"^DD",1130580001.101,1130580001.101,1.2,0)
2622NUMERATOR RULE SET^*P810.4'^PXRM(810.4,^7;7^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
2623"^DD",1130580001.101,1130580001.101,1.2,3)
2624Enter the reminder rule set to use for this measure.
2625"^DD",1130580001.101,1130580001.101,1.2,12)
2626If the type of the reminder list rule is a Rule Set.
2627"^DD",1130580001.101,1130580001.101,1.2,12.1)
2628S DIC("S")="I $P(^(0),U,3)=3"
2629"^DD",1130580001.101,1130580001.101,1.2,21,0)
2630^^5^5^3120716^
2631"^DD",1130580001.101,1130580001.101,1.2,21,1,0)
2632This is the numerator reminder rule set to use for the quality measure.
2633"^DD",1130580001.101,1130580001.101,1.2,21,2,0)
2634
2635"^DD",1130580001.101,1130580001.101,1.2,21,3,0)
2636The rule set is used to generate a patient list, which this package
2637"^DD",1130580001.101,1130580001.101,1.2,21,4,0)
2638referneces. The contents of the patient list will produce the count for
2639"^DD",1130580001.101,1130580001.101,1.2,21,5,0)
2640the measure. This count is for the numerator.
2641"^DD",1130580001.101,1130580001.101,1.2,"DT")
26423120716
2643"^DD",1130580001.101,1130580001.101,1.5,0)
2644NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q
2645"^DD",1130580001.101,1130580001.101,1.5,.1)
2646LIST OF PATIENTS THAT DO NOT MEET THE REQUIREMENTS
2647"^DD",1130580001.101,1130580001.101,1.5,"DT")
26483110809
2649"^DD",1130580001.101,1130580001.101,1.51,0)
2650ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q
2651"^DD",1130580001.101,1130580001.101,1.51,.1)
2652NEGATIVE NUMERATOR LIST IN C0Q PATIENT LIST FILE
2653"^DD",1130580001.101,1130580001.101,1.51,"DT")
26543110809
2655"^DD",1130580001.101,1130580001.101,2,0)
2656DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q
2657"^DD",1130580001.101,1130580001.101,2,.1)
2658MEASURE DENOMINATOR PATIENT LIST
2659"^DD",1130580001.101,1130580001.101,2,"DT")
26603101012
2661"^DD",1130580001.101,1130580001.101,2.1,0)
2662ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q
2663"^DD",1130580001.101,1130580001.101,2.1,"DT")
26643110805
2665"^DD",1130580001.101,1130580001.101,2.2,0)
2666DENOMINATOR RULE SET^*P810.4'^PXRM(810.4,^7;8^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
2667"^DD",1130580001.101,1130580001.101,2.2,3)
2668Enter the reminder rule set to use for this measure.
2669"^DD",1130580001.101,1130580001.101,2.2,12)
2670If the type of the reminder list rule is a Rule Set.
2671"^DD",1130580001.101,1130580001.101,2.2,12.1)
2672S DIC("S")="I $P(^(0),U,3)=3"
2673"^DD",1130580001.101,1130580001.101,2.2,21,0)
2674^^5^5^3120716^
2675"^DD",1130580001.101,1130580001.101,2.2,21,1,0)
2676This is the denominator reminder rule set to use for the quality measure.
2677"^DD",1130580001.101,1130580001.101,2.2,21,2,0)
2678
2679"^DD",1130580001.101,1130580001.101,2.2,21,3,0)
2680The rule set is used to generate a patient list, which this package
2681"^DD",1130580001.101,1130580001.101,2.2,21,4,0)
2682referneces. The contents of the patient list will produce the count for
2683"^DD",1130580001.101,1130580001.101,2.2,21,5,0)
2684the measure. This count is for the denominator.
2685"^DD",1130580001.101,1130580001.101,2.2,"DT")
26863120716
2687"^DD",1130580001.101,1130580001.101,2.5,0)
2688EXTRACT DEFINITION^P810.2'^PXRM(810.2,^7;9^Q
2689"^DD",1130580001.101,1130580001.101,2.5,3)
2690Select a Reminder Extract Definition for this measure
2691"^DD",1130580001.101,1130580001.101,2.5,21,0)
2692^^4^4^3120726^
2693"^DD",1130580001.101,1130580001.101,2.5,21,1,0)
2694If this measure depends upon a reminder extract definition, you can add
2695"^DD",1130580001.101,1130580001.101,2.5,21,2,0)
2696this extract definition here. This will alter how the Quality Measures
2697"^DD",1130580001.101,1130580001.101,2.5,21,3,0)
2698package computes the measure to use the extract in addition and prior to
2699"^DD",1130580001.101,1130580001.101,2.5,21,4,0)
2700the rule sets.
2701"^DD",1130580001.101,1130580001.101,2.5,"DT")
27023120726
2703"^DD",1130580001.101,1130580001.101,3,0)
2704QRDA TEMPLATE ROOT^F^^0;4^K:$L(X)>120!($L(X)<3) X
2705"^DD",1130580001.101,1130580001.101,3,.1)
2706MEASURE TEMPLATE ROOT FOR QRDA DOCUMENT
2707"^DD",1130580001.101,1130580001.101,3,3)
2708Answer must be 3-120 characters in length
2709"^DD",1130580001.101,1130580001.101,3,"DT")
27103101012
2711"^DD",1130580001.101,1130580001.101,3.1,0)
2712QRDA MEASURE SYSTEM OID^CJ^^ ; ^S X="2.16.840.1.113883.3.249.12"
2713"^DD",1130580001.101,1130580001.101,3.1,.1)
2714QRDA SYSTEM OID (FIXED)
2715"^DD",1130580001.101,1130580001.101,3.1,9.01)
2716
2717"^DD",1130580001.101,1130580001.101,3.1,9.1)
2718S X="2.16.840.1.113883.3.249.12"
2719"^DD",1130580001.101,1130580001.101,3.1,"DT")
27203101012
2721"^DD",1130580001.101,1130580001.101,3.2,0)
2722QRDA CODE^F^^4;1^K:$L(X)>80!($L(X)<1) X
2723"^DD",1130580001.101,1130580001.101,3.2,.1)
2724QRDA MEASURE CODE
2725"^DD",1130580001.101,1130580001.101,3.2,3)
2726Answer must be 1-80 characters in length
2727"^DD",1130580001.101,1130580001.101,3.2,"DT")
27283101012
2729"^DD",1130580001.101,1130580001.111,0)
2730VERY LONG DESCRIPTION SUB-FIELD^^.01^1
2731"^DD",1130580001.101,1130580001.111,0,"DT")
27323101013
2733"^DD",1130580001.101,1130580001.111,0,"NM","VERY LONG DESCRIPTION")
2734
2735"^DD",1130580001.101,1130580001.111,0,"UP")
27361130580001.101
2737"^DD",1130580001.101,1130580001.111,.01,0)
2738VERY LONG DESCRIPTION^Wx^^0;1
2739"^DD",1130580001.101,1130580001.111,.01,.1)
2740LONGER DESCRIPTION - IF IT DOESN'T FIT IN .6
2741"^DD",1130580001.101,1130580001.111,.01,3)
2742LONGER DESCRIPTION - INSTEAD OF LONG DESCRIPTION
2743"^DD",1130580001.101,1130580001.111,.01,"DT")
27443101013
2745"^DIC",1130580001.101,1130580001.101,0)
2746C0Q QUALITY MEASURE^1130580001.101
2747"^DIC",1130580001.101,1130580001.101,0,"GL")
2748^C0Q(101,
2749"^DIC",1130580001.101,"B","C0Q QUALITY MEASURE",1130580001.101)
2750
2751**END**
2752**END**
Note: See TracBrowser for help on using the repository browser.